<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1312200329
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Nucala
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MEPOLIZUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4709.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Glaxo Operations UK Ltd " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Glaxo Operations UK Ltd 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DX09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>q This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See end of the leaflet for how to report side effects. <!--[if supportFields]><span style='font-size:14.0pt;
font-family:"Arial Bold",serif;mso-bidi-font-family:Arial;mso-fareast-language:
EN-US;mso-bidi-font-weight:bold'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_70ec9a67-b32b-4123-9307-df22d054bc76 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:14.0pt;font-family:"Arial Bold",serif;mso-bidi-font-family:
Arial;mso-fareast-language:EN-US;mso-bidi-font-weight:bold'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>NUCALA is a prescription medicine:</strong></p><p>o&nbsp;&nbsp; for the add-on maintenance treatment of <strong>severe asthma</strong> in people 12 years of age and older whose asthma is not controlled with their current asthma medicines. NUCALA helps prevent severe asthma attacks (exacerbations).</p><p>NUCALA is not used to treat sudden breathing problems that occur with asthma.</p><p>o&nbsp;&nbsp; for add-on maintenance treatment of chronic rhinosinusitis with <strong>nasal polyps</strong> <strong>(CRSwNP)</strong> in adults whose disease is not controlled with nasal corticosteroids. NUCALA helps reduce symptoms (e.g., nasal congestion, nasal discharge, mucus in the throat, loss of smell). NUCALA helps reduce the size of your nasal polyps and the use of oral corticosteroid medicines. NUCALA helps prevent surgery for your nasal polyps.</p><p>o&nbsp;&nbsp; for the treatment of adults with <strong>eosinophilic granulomatosis with polyangiitis (EGPA)</strong>. NUCALA helps reduce symptoms and flares, and it may allow your healthcare provider to reduce your oral corticosteroid medicine.</p><p>o&nbsp;&nbsp; for the treatment of people 12 years of age and older with <strong>hypereosinophilic syndrome (HES)</strong>. NUCALA helps reduce symptoms and prevent flares.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines such as NUCALA reduce blood eosinophils. Eosinophils are a type of white blood cells that may contribute to your disease.</p><p>It is not known if NUCALA is safe and effective in children with severe asthma under 6 years of age.</p><p>It is not known if NUCALA is safe and effective in children and adolescents with CRSwNP or EGPA under 18 years of age.</p><p>It is not known if NUCALA is safe and effective in children with HES under 12 years of age.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use NUCALA</strong><!--[if supportFields]><b><span
lang=EN-US style='mso-bidi-font-size:12.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-fareast-font-family:"MS Mincho";mso-font-kerning:16.0pt;mso-ansi-language:
EN-US;mso-fareast-language:JA;layout-grid-mode:line'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_800dfc1d-3ca7-4ab1-ae54-f3cf2176697c
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='mso-bidi-font-size:12.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-fareast-font-family:"MS Mincho";mso-font-kerning:16.0pt;mso-ansi-language:
EN-US;mso-fareast-language:JA;layout-grid-mode:line'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>If you are <strong>allergic</strong> to mepolizumab or any of the ingredients in NUCALA. See the end of this leaflet for a complete list of ingredients in NUCALA (see section 6).</p><p><strong><em>&egrave; </em></strong>Check with your doctor if you think this applies to you.</p><p>&nbsp;</p><p><strong>Before receiving NUCALA, tell your healthcare provider about all of your medical conditions, including if you:</strong><!--[if supportFields]><b><span
lang=EN-US style='mso-bidi-font-size:12.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-fareast-font-family:"MS Mincho";mso-font-kerning:16.0pt;mso-ansi-language:
EN-US;mso-fareast-language:JA;layout-grid-mode:line'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_37f66560-270b-4e69-93ee-2c69d786c651
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='mso-bidi-font-size:12.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-fareast-font-family:"MS Mincho";mso-font-kerning:16.0pt;mso-ansi-language:
EN-US;mso-fareast-language:JA;layout-grid-mode:line'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a parasitic (helminth) infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking oral or inhaled corticosteroid medicines. <strong>Do not</strong> stop taking your corticosteroid medicines unless instructed by your healthcare provider. This may cause other symptoms that were controlled by the corticosteroid medicine to come back.</p><p><strong>Other medicines and NUCALA</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not stop taking your other medicines unless instructed to do so by your healthcare provider.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant or plan to become pregnant, ask your healthcare provider for advice before using NUCALA. It is not known if NUCALA may harm your unborn baby.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will use NUCALA and breastfeed. You should not do both without talking with your healthcare provider first.</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Driving and using machines</strong><!--[if supportFields]><b><span style='font-size:
13.0pt;line-height:115%;font-family:"Arial",sans-serif;mso-fareast-font-family:
Calibri;mso-fareast-language:EN-US'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_185967f9-3b87-4af2-8321-763f68cd0f2d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-fareast-font-family:Calibri;mso-fareast-language:EN-US'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong><em>&nbsp;</em></strong></p><p>The possible side effects of NUCALA are unlikely to affect your ability to drive or use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your healthcare provider will prescribe the dose that is right for you depending on what you are being treated for.</p><p><strong>When injection is given by a healthcare provider:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A healthcare provider will inject NUCALA under your skin (subcutaneously) every 4 weeks.</p><p><strong>When injection is given by a patient or patient caregiver with a prefilled syringe or prefilled autoinjector:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use NUCALA every 4 weeks exactly as your healthcare provider tells you to.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Read the Instructions for Use that comes with NUCALA for instructions about the right way to give your injections at home.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NUCALA may be prescribed as a single-dose prefilled autoinjector or as a single-dose prefilled syringe for people 12 years of age and older.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before you use NUCALA, your healthcare provider will show you or your caregiver how to give the injections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should inject NUCALA under your skin (subcutaneously) into your thigh or stomach (abdomen). Also, a caregiver may give the injection in your upper arm.</p><p>If you miss a dose, inject a dose as soon as possible. Then continue (resume) your injection on your regular dosing schedule. If you do not notice that you have missed a dose until it is time for your next scheduled dose, then inject the next scheduled dose as planned. If you are not sure when to inject NUCALA, call your healthcare provider.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>NUCALA can cause serious side effects, including:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>allergic (hypersensitivity) reactions, including anaphylaxis.</strong> Serious allergic reactions can happen after you get your NUCALA injection. Allergic reactions can sometimes happen hours or days after you get a dose of NUCALA. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp; swelling of your face, mouth, and tongue</p></td><td style="vertical-align:top"><p>o&nbsp;&nbsp; breathing problems</p></td></tr><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp; fainting, dizziness, feeling lightheaded (low blood pressure)</p></td><td style="vertical-align:top"><p>o&nbsp;&nbsp; rash</p></td></tr><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp; hives</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>herpes zoster infections.</strong> Herpes zoster infections that can cause shingles have happened in people who received NUCALA.</p><p>&nbsp;</p><p><strong>The most common side effects of NUCALA include;</strong> headache, injection site reactions (pain, redness, swelling, itching, or a burning feeling at the injection site), back pain, and tiredness (fatigue).</p><p>Mouth/throat pain and joint pain have been reported with CRSwNP.</p><p>These are not all of the possible side effects of NUCALA.</p><p>&nbsp;</p><p><strong><em>&egrave; </em></strong><strong>Tell your doctor or pharmacist </strong><strong>if any of the side effects listed becomes severe or troublesome, or if you notice any side effects not listed in this leaflet.</strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use NUCALA after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in refrigerator (2-8&ordm;C). Do not freeze.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original carton to protect from light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The pre-filled pen and pre-filled syringe can be removed from the refrigerator and kept in its unopened carton for up to 7 days at room temperature (up to 30&deg;C), when protected from light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Must be administered within 8 hours once the pack is opened. Discard if not administered within 8 hours.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What NUCALA contains</strong></p><p>&nbsp;</p><p>The active substance is mepolizumab.</p><p>Each 1&nbsp;mL pre-filled pen and syringe contains 100&nbsp;mg mepolizumab.</p><p>Other ingredients are:</p><p>Sucrose, sodium phosphate dibasic heptahydrate, citric acid monohydrate, polysorbate 80, EDTA disodium dehydrate and Water for injection.</p><p><strong><em>NSTRUCTIONS FOR USE</em></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:612px"><tbody><tr><td style="vertical-align:top"><p><strong>NUCALA</strong></p><p><strong>(mepolizumab)</strong></p><p>injection, for subcutaneous use</p><p><strong>Solution for injection in pre-filled pen (auto-injector)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Important information</strong></p></td></tr><tr><td style="vertical-align:top"><p>NUCALA is a prescription medicine that is injected under the skin (subcutaneous) from a single-dose prefilled autoinjector. You and your caregiver should be trained on how to prepare and perform your injection before trying to do it yourself.</p><p>The following instructions provide the information you need to correctly use the prefilled autoinjector with yellow needle guard.</p><p>Before starting your injection, it is important that you read and understand these instructions and then carefully follow them so that you complete each step successfully.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Storage information</strong></p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the refrigerator between 2&deg;C to 8&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep in the original carton until time of use to protect from light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not</strong> freeze. <strong>Do not</strong> shake. Keep away from heat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If necessary, an unopened carton can be stored outside the refrigerator at up to 30&deg;C for up to 7 days.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Safely throw away the prefilled autoinjector if it is left out of the refrigerator in the unopened carton for more than 7 days.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The prefilled autoinjector must be used within 8 hours after you take it out of the carton. Safely throw it away if it is not used within 8 hours.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Safely throw away medicine that is out of date or no longer needed.</p><p><strong>Keep NUCALA and all medicines out of the reach of children.</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Warnings</strong></p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not</strong> use the prefilled autoinjector more than 1 time. Throw away the autoinjector in sharps disposal container after your injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not</strong> share the prefilled autoinjector with other people. You may give other people a serious infection, or you may get a serious infection from them.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not</strong> use the prefilled autoinjector if it was dropped or looks damaged.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Know your prefilled autoinjector</strong></p></td></tr><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1034" type="#_x0000_t75"
   style='width:296.25pt;height:225pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="395" height="300" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p><strong>Supplies in carton</strong></p></td></tr><tr><td style="vertical-align:top"><p>1 Prefilled autoinjector</p></td></tr><tr><td style="vertical-align:top"><p><strong>Supplies not in carton</strong></p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alcohol swab</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cotton ball or gauze</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adhesive bandage</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sharps disposal container<br />(See Step 8 &ldquo;Throw away your used autoinjector&rdquo; at the end of this Instructions for Use for proper disposal instructions.)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Prepare</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>1.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Take out the prefilled autoinjector</strong></p></td></tr><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_21"
   o:spid="_x0000_i1033" type="#_x0000_t75" style='width:291.75pt;height:147pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="389" height="196" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take the carton out of the refrigerator and make sure the security seals are not broken.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the tray from the carton.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Peel off the clear plastic cover from the corner of the tray.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Holding the middle of the prefilled autoinjector (near the inspection window), carefully take the prefilled autoinjector out of the tray.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place the prefilled autoinjector on a clean, flat surface at room temperature away from direct sunlight and out of the reach of children.</p><p>o&nbsp;&nbsp; <strong>Do not</strong> use the prefilled autoinjector if the security seal on the carton is broken.</p><p>o&nbsp;&nbsp; <strong>Do not</strong> remove the clear needle cap at this step.</p></td></tr><tr><td style="vertical-align:top"><p><strong>2.&nbsp;&nbsp; </strong><strong>Inspect and wait 30 minutes before use</strong></p></td></tr><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_11"
   o:spid="_x0000_i1032" type="#_x0000_t75" style='width:292.5pt;height:147.75pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image005.jpg"
    o:title="RGB 3_PEN_Inspect and come to room temperature"/>
  </v:shape><![endif]--><img width="390" height="197" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check that the expiration date on the label of the prefilled autoinjector has not passed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Look at the medicine in the inspection window. It should be clear to pale yellow to pale brown in color and without cloudiness or particles.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is normal to see 1 or more air bubbles.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wait 30 minutes (and no more than 8 hours) before use.</p><p>o&nbsp;&nbsp; <strong>Do not</strong> use if the expiration date has passed.</p><p>o&nbsp;&nbsp; <strong>Do not</strong> warm your prefilled autoinjector in a microwave, hot water, or direct sunlight.</p><p>o&nbsp;&nbsp; <strong>Do not</strong> use if the medicine is cloudy, discolored or has particles.</p><p>o&nbsp;&nbsp; <strong>Do not</strong> use the prefilled autoinjector if it has been left out of the carton for more than 8 hours.</p></td></tr><tr><td style="vertical-align:top"><p><strong>3.&nbsp;&nbsp; </strong><strong>Choose your injection site</strong></p></td></tr><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_36"
   o:spid="_x0000_i1031" type="#_x0000_t75" style='width:297pt;height:150.75pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image007.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="396" height="201" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image008.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can inject in your thighs or abdomen.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are giving the injection to someone else as a caregiver or healthcare provider, you can also inject into their upper arm.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you need more than 1 injection to complete your dose, leave at least 2 inches between each injection site.</p><p>o&nbsp;&nbsp; <strong>Do not</strong> inject where your skin is bruised, tender, red, or hard.</p><p>o&nbsp;&nbsp; <strong>Do not</strong> inject within 2 inches of your belly button.</p></td></tr><tr><td style="vertical-align:top"><p><strong>4.&nbsp;&nbsp; </strong><strong>Clean your injection site</strong></p></td></tr><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_37"
   o:spid="_x0000_i1030" type="#_x0000_t75" style='width:291.75pt;height:147pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image009.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="389" height="196" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image010.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wash your hands with soap and water.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clean your injection site by wiping your skin with an alcohol swab and allowing your skin to air dry.</p><p>o&nbsp;&nbsp; <strong>Do not</strong> touch your cleaned injection site again until you have finished your injection.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Inject</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>5.&nbsp;&nbsp; </strong><strong>Remove the clear needle cap</strong></p></td></tr><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_7"
   o:spid="_x0000_i1029" type="#_x0000_t75" style='width:297pt;height:150pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image011.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="396" height="200" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image012.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the clear needle cap from the prefilled autoinjector by pulling it straight off, away from the yellow needle guard (as shown). It may take some force to remove the clear needle cap.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may see a drop of medicine at the end of the needle. This is normal.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Make sure you inject within 5 minutes after you remove the clear needle cap.</p><p>o&nbsp;&nbsp; <strong>Do not</strong> press the yellow needle guard with your fingers. This could activate the prefilled autoinjector too soon and cause a needle injury.</p><p>o&nbsp;&nbsp; <strong>Do not</strong> put the clear needle cap back onto the prefilled autoinjector. This could accidentally start the injection.</p></td></tr><tr><td style="vertical-align:top"><p><strong>6.&nbsp;&nbsp; </strong><strong>Start your injection</strong></p></td></tr><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_8"
   o:spid="_x0000_i1028" type="#_x0000_t75" style='width:297pt;height:150pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image013.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="396" height="200" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image014.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold the prefilled autoinjector with its inspection window facing you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place the prefilled autoinjector straight onto your injection site with the yellow needle guard flat on the surface of your skin, as shown.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To start your injection, push the autoinjector all the way down and keep the autoinjector held down against your skin. This will make the yellow needle guard slide up into the autoinjector.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should hear the 1st click to let you know your injection has started.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The yellow indicator will move down through the inspection window as you receive your dose.</p><p>o&nbsp;&nbsp; <strong>Do not</strong> lift the autoinjector at this step as it may result in an incomplete injection.</p><p>o&nbsp;&nbsp; <strong>Do not</strong> use the autoinjector if the yellow needle guard does not slide up into the autoinjector. Throw it away in sharps container.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not</strong> try to use the autoinjector upside down with the yellow needle guard facing upward against your thumb.</p></td></tr><tr><td style="vertical-align:top"><p><strong>7.&nbsp;&nbsp; </strong><strong>Complete your injection</strong></p></td></tr><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_9"
   o:spid="_x0000_i1027" type="#_x0000_t75" style='width:297pt;height:150pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image015.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="396" height="200" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image016.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your injection may take up to 15 seconds to complete.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Continue to hold the autoinjector down until you hear the 2nd click, the stopper has stopped moving, and the inspection window is filled with the yellow indicator.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After you hear the 2nd click, continue to hold and count to 5 before you lift the autoinjector away from your skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you do not hear the 2nd click:</p><p>&nbsp;&nbsp;&nbsp; o&nbsp;&nbsp; check that the inspection window is filled with the yellow indicator, or</p><p>&nbsp;&nbsp;&nbsp; o&nbsp;&nbsp; hold the autoinjector down for 15 seconds to make sure the injection is complete.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There may be a small drop of blood at the injection site. This is normal. Press a cotton ball or gauze on the area and apply an adhesive bandage if you need it.</p><p>o&nbsp;&nbsp; <strong>Do not</strong> lift the autoinjector until you have heard the 2nd click, the window has been filled with the yellow indicator, and you have counted to 5.</p><p>o&nbsp;&nbsp; <strong>Do not</strong> rub your injection site.</p><p>o&nbsp;&nbsp; <strong>Do not</strong> put the clear needle cap back onto the autoinjector.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dispose</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>8.&nbsp;&nbsp; </strong><strong>Throw away your used autoinjector</strong></p></td></tr><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_10"
   o:spid="_x0000_i1026" type="#_x0000_t75" style='width:297pt;height:150pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image017.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="396" height="200" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image018.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p>Put your used autoinjector and clear needle cap in sharps disposal container right away after use.</p><p>If you do not have sharps disposal container, you may use a household container that is:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; made of heavy-duty plastic;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; able to close with a tight-fitting, puncture-resistant lid, without sharps being able to come out;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upright and stable during use;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; leak-resistant; and</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; properly labeled to warn of hazardous waste inside the container.</p><p>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of it. There may be state or local laws about how you should throw away used autoinjectors.</p><p>o&nbsp;&nbsp; <strong>Do not</strong> throw away your used sharps disposal container in your household trash unless your community guidelines permit this.</p><p>o&nbsp;&nbsp; <strong>Do not</strong> recycle your used sharps disposal container.</p><p><strong>Keep your sharps disposal container out of the reach of children.</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Frequently asked questions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>1.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Can I change (rotate) the injection site for the prefilled autoinjector?</strong></p><p>You may change (rotate) the site (thigh, abdomen, or upper arm) or move the autoinjector as long as you have not started pressing down. When the yellow needle guard is pressed, your injection will start right away.</p><p><strong>2.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Why do I need to inject within 5 minutes of removing the clear needle cap?</strong></p><p>This prevents the medicine from drying in the needle. It could affect how much medicine you get.</p><p><strong>3.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>What happens if I remove the autoinjector before the 2<sup>nd</sup> click, the stopper has stopped moving, or the inspection window is not filled with the yellow indicator?</strong></p><p>If this happens, you may not have received your full dose.</p><p><strong>4.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Who do I contact if I need help with my injection?</strong></p><p>Your healthcare provider will be able to help you with any more questions you might have.</p><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_41" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:54.75pt;
   height:34.5pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image019.jpg"
    o:title="GSK_L_2D_CMYK_K"/>
  </v:shape><![endif]--><img width="73" height="46" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image020.jpg" /></p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Solution for injection in pre-filled pen (auto-injector)
NUCALA is supplied as a clear, colourless to pale yellow to pale brown solution in a 1 mL siliconised, Type I glass syringe with 0.5 inch (12.7 mm), 29 gauge, stainless steel needle assembled as an auto-injector.
	NUCALA is available in a pack containing 1 single-use pre-filled pen.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by:</strong></p><p>Glaxo Operations UK Ltd*, Barnard Castle, UK</p><p><strong>Marketing Authorisation Holder:</strong></p><p>Glaxo Saudi Arabia Ltd.*, Jeddah, Kingdom of Saudi Arabia.</p><p>*member of the GSK group of companies</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                NUCALA is a trademark owned by or licensed to the GSK group of companies.
© 2021 GSK group of companies. All Rights Reserved.

Version Number: US version 29-07-2021
Version date: 29 July 2021

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>&nbsp;</strong>هذا الدواء يخضع لرقابة إضافية حتى يتم تحديد معلومات السلامة الجديدة بشكل أسرع. يمكنك المساعدة بالإبلاغq</p><p dir="RTL">عن أي أعراض جانبية قد تواجهك. راجع نهاية النشرة لمعرفة كيفية التبليغ عن الأعراض الجانبية</p><p dir="RTL"><strong>يُصرف دواء</strong><strong> </strong><strong>نوكالا</strong><strong> </strong><strong>بموجب</strong><strong> </strong><strong>وصفة</strong><strong> </strong><strong>طبية</strong><strong>:</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لتقديم حماية علاجية إضافية خاصة <strong>بمرض</strong><strong> </strong><strong>الربو</strong><strong> </strong><strong>الشديد </strong>عند الأشخاص الذين تبلغ أعمارهم 12عاماً فما فوق، الذين لا يخضع مرض الربو الذين يعانون منه للسيطرة باستخدام أدوية الربو الحالية. يساعد دواء نوكالا على تفادي أزمات الربو الشديدة (النوبات).</p><p dir="RTL">لا يستخدم دواء نوكالا لعلاج مشاكل التنفس المفاجئة التي تحدث مع الربو.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لتقديم حماية علاجية إضافية خاصة <strong>بإلتهاب</strong><strong> الجيوب الأنفية المزمن المصحوب بالزوائد الأنفية</strong> &nbsp;(CRSwNP)للبالغين الذين لا يخضع مرضهم للسيطرة باستخدام الكورتيكوستيرويدات الأنفية. يساعد نوكالا على التخفيف من الأعراض (مثل: احتقان الأنف، الإفرازات الأنفية، مخاط الحلق، فقدان حاسة الشم). يساعد نوكالا على تقليص حجم الزوائد الأنفية و يحد من استخدام أدوية الكورتيكوستيرويدات عن طريق الفم. يساعد نوكالا على منع التدخل الجراحي في حالة الزوائد الأنفية.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج البالغين المصابين بإلتهاب الأوعية الدموية الآنْضِدَادِي الإيوزينوفيليي الحبيبي (EGPA). يساعد دواء نوكالا في تخفيف الأعراض وتفاقم المرض، وقد يتيح لمقدم الرعاية الصحية التقليل من أدوية الكورتيكوستيرويدات التي تأخذها عن طريق الفم.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج الأشخاص الذين تبلغ أعمارهم 12 عامًا فما فوق، المصابين <strong>بمتلازمة</strong><strong> </strong><strong>فرط</strong><strong> </strong><strong>اليوزينيات</strong><strong> </strong>(HES). يساعد دواء نوكالا في تقليل الأعراض ومنع تفاقم المرض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مثل دواء نوكالا تقلل من الحمضات في الدم. الحمضات هي نوع من خلايا الدم البيضاء التي قد تساهم في مرضك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المعروف ما إذا كان دواء نوكالا آمنًا وفعالاً بالنسبة للأطفال الذين يعانون من الربو الشديد، الذين تقل أعمارهم عن 6 أعوام.</p><p dir="RTL">من غير المعروف ما إذا كان دواء نوكالا آمنًا وفعالاً بالنسبة للأطفال والمراهقين الذين يعانون من إلتهاب الجيوب الأنفية المصحوب بالزوائد الأنفية (CRSwNP) أو إلتهاب الأوعية الدموية الآنْضِدَادِي الإيوزينوفيليي الحبيبي (EGPA)، الذين تقل أعمارهم عن 18عامًا.</p><p dir="RTL">من غير المعروف ما إذا كان دواء نوكالا آمنًا وفعالاً بالنسبة للأطفال الذين يعانون من متلازمة فرط اليوزينيات HES))، الذين تقل أعمارهم عن 12 عامًا.<!--[if supportFields]><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-SA'><span style='mso-element:field-begin'></span> </span><span
lang=EN-US dir=LTR style='font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-SA'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
lang=EN-US style='font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-SA'><span dir=RTL></span><span dir=RTL></span> </span><span
lang=EN-US dir=LTR style='font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-SA'>VAULT_ND_f5788637-e8f3-4772-baef-f956167e0e69 \*
MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span lang=EN-US
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-bidi-language:
AR-SA'><span dir=RTL></span><span dir=RTL></span> </span><span lang=AR-SA
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-bidi-language:
AR-SA'><span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-SA'><span style='mso-element:field-end'></span></span><![endif]--><!--[if supportFields]><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-SA'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span></span><span lang=EN-US dir=LTR
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-bidi-language:
AR-SA'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
lang=EN-US style='font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-SA'><span dir=RTL></span><span dir=RTL></span> </span><span
lang=EN-US dir=LTR style='font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-SA'>VAULT_ND_f5788637-e8f3-4772-baef-f956167e0e69 \*
MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span lang=EN-US
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-bidi-language:
AR-SA'><span dir=RTL></span><span dir=RTL></span> </span><span lang=AR-SA
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-bidi-language:
AR-SA'><span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-SA'><span style='mso-element:field-end'></span></span><![endif]--></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم استخدام </strong><strong>نوكالا</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:14.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
major-bidi;mso-bidi-language:AR-SA'><span style='mso-element:field-begin'></span>
</span></b><b><span lang=EN-US dir=LTR style='font-size:14.0pt;font-family:
"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-SA'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span lang=EN-US style='font-size:14.0pt;
font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-SA'><span
dir=RTL></span><span dir=RTL></span> </span></b><b><span lang=EN-US dir=LTR
style='font-size:14.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-SA'>VAULT_ND_14d71504-1956-4ee2-842e-ec1d013ba944 \*
MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
lang=EN-US style='font-size:14.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
major-bidi;mso-bidi-language:AR-SA'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span
lang=AR-SA style='font-size:14.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
major-bidi;mso-bidi-language:AR-SA'><span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:14.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
major-bidi;mso-bidi-language:AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">&ccedil;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية تجاه مادة &quot; میپولیزوماب&quot; أو أي من مكونات دواء نوكالا. راجع نهاية نشرة الدواء هذه للحصول على قائمة كاملة بالمكونات في دواء نوكالا (المدرجة في القسم 6).</p><p dir="RTL">&ccedil;&nbsp;&nbsp;&nbsp; <strong>تحدث إلى طبيبك</strong> إذا كنت تعتقد أن هذا الأمر ينطبق عليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قبل</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>تتلقى</strong><strong> </strong><strong>دواء</strong><strong> </strong><strong>نوكالا،</strong><strong> </strong><strong>أخبر</strong><strong> </strong><strong>مقدم</strong><strong> </strong><strong>الرعاية</strong><strong> </strong><strong>الصحية</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>جميع</strong><strong> </strong><strong>حالاتك</strong><strong> </strong><strong>المرضيّة،</strong><strong> </strong><strong>بما</strong><strong> </strong><strong>في</strong><strong> </strong><strong>ذلك</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من عدوى طفيلية (الديدان المعوية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تستخدم أدوية الكورتيزون عن طريق الفم أو المستنشقة.<strong> </strong><strong>لا</strong> تتوقف عن تناول أدوية الكورتيزون ما لم يطلب منك مقدم الرعاية الصحية خلاف ذلك. قد يتسبب هذا في عودة ظهور أعراض أخرى جرى التحكم فيها سابقًا بواسطة أدوية الكورتيزون.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى ونوكالا</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر مقدم الرعاية الصحية عن جميع الأدوية التي تستخدمها، بما فيها الوصفات الطبية والأدوية التي تُصرف دون وصفة طبية، والفيتامينات، والمكمّلات العشبية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تتوقف عن تناول أدويتك الأخرى ما لم يطلب منك مقدم الرعاية الصحية ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً أو تخططين للحمل، استشيري مقدم الرعاية الصحية قبل استخدام نوكالا. من غير المعروف ما إذا كان دواء نوكالا سيؤذي جنينكِ.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ ترضعين طفلك رضاعة طبيعية أو تخططين للإرضاع. يجب أن تقرري أنت ومقدم الرعاية الصحية ما إذا كنتِ ستستخدمين دواء نوكالا وترضعين رضاعة طبيعية. ينبغي ألا تفعلي كلا الأمرين دون التحدث مع مقدم الرعاية الصحية أولاً.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المرجح أن تؤثر الآثار الجانبية المحتملة لدواء نوكالا على قدرتك على القيادة أو استخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيصف لك مقدم الرعاية الصحية الجرعة المناسبة لك وفقاً لمرضك.</p><p dir="RTL"><strong>عندما</strong><strong> </strong><strong>يعطيك</strong><strong> </strong><strong>مقدم</strong><strong> </strong><strong>الرعاية</strong><strong> </strong><strong>الصحية</strong><strong> </strong><strong>الحقنة</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيحقن مقدم الرعاية الصحية دواء نوكالا تحت الجلد مرة كل 4 أسابيع.</p><p dir="RTL"><strong>عندما</strong><strong> </strong><strong>يستخدم </strong><strong>المريض</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>مقدم</strong><strong> </strong><strong>الرعاية</strong><strong> </strong><strong>الصحية</strong><strong> </strong><strong>الحقنة</strong><strong> </strong><strong>مسبقة</strong><strong> </strong><strong>التعبئة</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>المحقنة</strong><strong> </strong><strong>الذاتية</strong><strong> </strong><strong>مسبقة</strong><strong> </strong><strong>التعبئة</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدم دواء نوكالا كل أربعة أسابيع، تمامًا مثلما يخبرك مقدم الرعاية الصحية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اقرأ تعليمات الاستخدام التي تأتي مع دواء نوكالا للحصول على الإرشادات الصحيحة لإعطاء الحقن في المنزل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن وصف دواء نوكالا على أنه محقنة ذاتية مسبقة التعبئة بجرعة واحدة أو حقنة مسبقة التعبئة بجرعة واحدة، للأشخاص الذين تبلغ أعمارهم 12 عامًا فما فوق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل أن تستخدم دواء نوكالا، سيوضح مقدم الرعاية الصحية لك ولمقدم الرعاية للمريض كيفية إعطاء الحقن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تحقن دواء نوكالا تحت الجلد، في الفخذ أو المعدة (البطن). أيضًا، قد يعطيك مقدم الرعاية الحقنة في الجزء العلوي من ذراعك.</p><p dir="RTL">إذا فاتك موعد جرعتك، احقن الجرعة في أقرب وقت ممكن. ثم تابع (استأنف) الحقن اعتمادًا على جدول الجرعات المعتاد. إذا لم تلاحظ أنك فوّت الجرعة حتى حان موعد الجرعة التالية، فاحقن الجرعة المقرّرة التالية كما هو مخطط لها. في حال لم تكن متأكدًا من موعد حقن دواء &quot;نوكالا&quot;، اتصل بمقدم الرعاية الصحية.<!--[if supportFields]><span lang=AR-SA style='font-family:
"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi;mso-bidi-language:AR-SA'><span
style='mso-element:field-begin'></span> </span><span lang=EN-US dir=LTR
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-bidi-language:
AR-SA'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
lang=EN-US style='font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-SA'><span dir=RTL></span><span dir=RTL></span> </span><span
lang=EN-US dir=LTR style='font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-bidi-language:AR-SA'>VAULT_ND_aa106033-fba5-455e-81d0-3ce5354dbc30 \*
MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span lang=EN-US
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-bidi-language:
AR-SA'><span dir=RTL></span><span dir=RTL></span> </span><span lang=AR-SA
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-bidi-language:
AR-SA'><span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يمكن</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>يسبب</strong><strong> </strong><strong>دواء</strong><strong> </strong><strong>نوكالا</strong><strong> </strong><strong>أعراضًا</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>خطيرة،</strong><strong> </strong><strong>بما</strong><strong> </strong><strong>في</strong><strong> </strong><strong>ذلك</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التفاعلات</strong><strong> </strong><strong>التحسُّسية</strong><strong> (</strong><strong>فرط</strong><strong> </strong><strong>الحساسية</strong><strong>)</strong><strong>،</strong><strong> </strong><strong>بما</strong><strong> </strong><strong>في</strong><strong> </strong><strong>ذلك</strong><strong> </strong><strong>التأق</strong>. يمكن أن تحدث تفاعلات حساسية خطيرة بعد أن تتلقى حقنة دواء نوكالا. يمكن أن تحدث تفاعلات الحساسية أحيانًا بعد ساعات أو أيام من تناول جرعة من دواء نوكالا. أخبر مقدّم الرعاية الصحية أو اطلب المساعدة الطارئة فورًا إذا عانيت من إحدى أعراض تفاعلات الحساسية التالية:</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورّم الوجه، ، أوالفم ، أو اللسان</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في التنفس</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء، والدوخة، والشعور بالدوار (انخفاض ضغط الدم)</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى</p></td><td style="vertical-align:top"><p dir="LTR">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>عدوى</strong><strong> </strong><strong>الهربس</strong><strong> </strong><strong>النطاقي</strong><strong>.</strong> سبق وأُصيب بعض الأشخاص الذين تلقوا دواء نوكالا، بعدوى الهربس النطاقي التي يمكن أن تسبب مرض الحزام الناري.</p><p dir="RTL"><strong>تشمل</strong><strong> </strong><strong>الأعراض</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>الأكثر</strong><strong> </strong><strong>شيوعًا</strong><strong> </strong><strong>لدواء</strong><strong> </strong><strong>نوكالا</strong><strong>:</strong> الصداع، وتفاعلات موضع الحقن (ألم، أو احمرار، أو تورم، أو حكة، أو شعور بالحرق في موضع الحقن)، وآلام الظهر، والإعياء (التعب).</p><p dir="RTL">سُجل ألم الفم/ الحلق والمفاصل مع إلتهاب الجيوب الأنفية المصحوب بالزوائد الأنفية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذه ليست جميع الأعراض الجانبية المحتملة لدواء نوكالا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&ccedil; <strong>أخبر</strong><strong> </strong><strong>الطبيب</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong> </strong><strong>في</strong><strong> </strong><strong>حالة</strong><strong> </strong><strong>تفاقم</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الأعراض</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>الموضحة</strong><strong> </strong><strong>هنا</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>أصبحت</strong><strong> </strong><strong>مزعجة،</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>لاحظت</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>أعراض</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>مبيَّنة</strong><strong> </strong><strong>في</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>النشرة</strong><strong>.</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="RTL"><strong>يجب</strong><strong> </strong><strong>حفظ الدواء</strong><strong> </strong><strong>بعيدًا</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>نظر</strong><strong> </strong><strong>ومتناول</strong><strong> </strong><strong>الأطفال</strong><strong>. </strong></li><li dir="RTL">لا تستخدم نوكالا بعد تاريخ انتهاء الصلاحية المدون على اللاصق والعبوة بعد كلمة EXP. تاريخ إنتهاء الصلاحية يشير إلى آخر يوم في الشهر.</li><li dir="RTL">يُخزن في الثلاجة في درجة حرارة بين <strong>2</strong> إلى <strong>8</strong> درجة مئوية. &nbsp;لا يجب تجميده.</li><li dir="RTL">يُحفظ في العبوة الأصلية لحمايته من الضوء.</li><li dir="RTL">يمكن إزالة قلم الحقن مسبق التعبئة والمحقنة مسبقة التعبئة من الثلاجة والبقاء عليهما في العبوة الغير مفتوحة حتى 7 أيام في درجة حرارة الغرفة (حتى 30 درجة مئوية)، بشرط حمايتها من الضوء.</li><li dir="RTL">يجب أن يتم إعطاء نوكالا خلال 8 ساعات بمجرد فتح العبوة. يجب التخلص منها إذا لم يتم إستخدامها خلال 8 ساعات.</li><li dir="RTL">لا تتخلص من الأدوية في مياه الصرف الصحي ولا المخلفات المنزلية. اسأل الصيدلي عن الطريقة المناسبة للتخلص من الأدوية التي لم تعد هناك حاجة لها. فهذا من شأنه أن يساعد في الحفاظ على البيئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات نوكالا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">المادة الفعَّالة بهذا الدواء هي میپولیزوماب.</p><p dir="RTL">يحتوي كل قلم للحقن&nbsp; أو محقنة مسبقة التعبئة على 100 ملجم من المیپولیزوماب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">سكروز، فوسفات الصوديوم ثنائي القاعدة سباعي الهيدرات، حمض السيتريك أحادي الهيدرات، بوليسوربات 80، ثنائي أمين الإيثيلين رباعي حمض الأسيتيك (EDTA) ثنائي الهيدرات ثنائي الصوديوم وماء للحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل</strong><strong> </strong><strong>نوكالا</strong><strong> </strong><strong>ومحتويات</strong><strong> </strong><strong>العبوة</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><u>محلول للحقن في قلم للحقن مسبق التعبئة (ذاتي الحقن)</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر نوكالا كسائل صافي، عديم اللون يميل إلى ما بين الأصفر الباهت والبني الباهت معبأ في محقنة زجاجية سيليكونية من النوع 1 مزودة بإبرة من الفولاذ المقاوم للصدأ بطول 0.5 بوصة (12.7 مليمتر) عيار 29، مجمعة كحاقن أتوماتيكي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر نوكالا في عبوة تحتوي على قلم للحقن مسبق التعبئة (ذاتي الحقن) واحد مخصص للاستخدام لمرة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>إرشادات الإستخدام:</em></strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:696px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>نوكالا</strong></p><p dir="RTL"><strong>(</strong><strong>میپولیزوماب</strong><strong>)</strong></p><p dir="RTL">حقن، تحت الجلد</p><p dir="RTL"><strong>قلم للحقن مسبق التعبئة (ذاتي الحقن)</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>معلومات مهمة</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">يُصرف دواء نوكالا بموجب وصفة طبية، يُحقن تحت الجلد باستخدام محقنة ذاتية مسبقة التعبئة بجرعة واحدة. يجب أن تتدرّب برفقة مقدم الرعاية الصحيّة بشأن كيفية تحضير وإعطاء الحقن ، قبل إجرائه &nbsp;بنفسك.</p><p dir="RTL">توفّر الإرشادات التالية، المعلومات الصحيحة التي تحتاجها لاستخدام المحقنة الذاتية مسبقة التعبئة المُرفقة بواقِ الإبرة الأصفر.</p><p dir="RTL">قبل البدء في &nbsp;&nbsp;الحقن ، من المهم أن تقرأ هذه التعليمات وتفهمها، ثم تتبعها بعناية حتى تكمل كل خطوة بنجاح.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>معلومات</strong> <strong>حول</strong><strong> التخزين</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ هذا الدواء في الثلاجة عند درجة حرارة تتراوح ما بين 2 درجة مئوية إلى 8 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظ به في علبة الكرتون الأصلية حتى يحين وقت الاستخدام، لحمايته من الضوء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تجمّد الدواء.<strong> </strong><strong>لا</strong> ترجّ الدواء. احفظ الدواء بعيدًا عن الحرارة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لزم الأمر، يمكن تخزين علبة الكرتون المغلقة خارج الثلاجة في درجة حرارة لا تتجاوز 30 درجة مئوية لمدة تصل إلى 7 أيام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخلّص من قلم الحقن مسبق التعبئة (ذاتي الحقن) بأمان، في حال ما إذا تُركت خارج الثلاجة، داخل علبة كرتون مغلقة، لأكثر من 7 أيام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب استخدام قلم الحقن مسبق التعبئة (ذاتي الحقن) في غضون 8 ساعات بعد إخراجها من علبة الكرتون. تخلص منها بأمان إذا لم تُستخدم خلال 8 ساعات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخلص بأمان من الأدوية منتهية الصلاحية أو التي لم تعد هناك حاجة إليها.</p><p dir="RTL"><strong>احتفظ</strong><strong> </strong><strong>بدواء</strong><strong> </strong><strong>نوكالا</strong><strong> </strong><strong>وكل</strong><strong> </strong><strong>الأدوية</strong><strong> </strong><strong>بعيدًا</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>متناول</strong><strong> </strong><strong>الأطفال</strong><strong>.</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>تحذيرات</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تستخدم قلم الحقن مسبق التعبئة (ذاتي الحقن) أكثر من مرة واحدة. تخلّص من قلم للحقن مسبق التعبئة (ذاتي الحقن) بعد تلقي الحقنة في حاوية التخلص من الأدوات الحادة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تتشارك حقنة دواء نوكالا مسبق التعبئة (ذاتي الحقن) مع أشخاص آخرين. قد تصيب الأشخاص الآخرين بعدوى خطيرة، أو قد تصاب بعدوى خطيرة منهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تستخدم قلم الحقن مسبق التعبئة (ذاتي الحقن) ، إذا سقطت، أو بدت تالفة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>اعرف</strong><strong> </strong><strong>قلم للحقن مسبق التعبئة (ذاتي الحقن)</strong><strong> </strong><strong>الخاص</strong><strong> </strong><strong>بك</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>المؤشر الأصفر (يصبح مرئيًا عندما يكتمل الحقن)</strong></p><p>&nbsp;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>غطاء الإبرة الشفاف</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>واقِ الإبرة الأصفر (الإبرة في الداخل)</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>السدادة</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>نافذة</strong><strong> </strong><strong>الفحص</strong><strong> (</strong><strong>الدواء</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الداخل</strong><strong>)</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>بعد</strong><strong> </strong><strong>الاستخدام</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>الملصق</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>قبل</strong><strong> </strong><strong>الاستخدام</strong></p></td></tr></tbody></table><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الأدوات</strong><strong> </strong><strong>الموجودة</strong><strong> </strong><strong>داخل</strong><strong> </strong><strong>علبة</strong><strong> </strong><strong>الكرتون</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">1 قلم الحقن مسبق التعبئة (ذاتي الحقن)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الأدوات</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>الموجودة</strong><strong> </strong><strong>داخل</strong><strong> </strong><strong>علبة</strong><strong> </strong><strong>الكرتون</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مسحة كحول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قطعة من القطن أو ضمادة من الشاش</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضمادة لاصقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاوية للتخلص من الأدوات الحادة<br />(انظر الخطوة رقم 8 &quot;تخلّص من قلم للحقن مسبق التعبئة (المحقنة الذاتية)&quot; في نهاية إﺭﺷﺎﺩﺍﺕ الاستخدام هذه، للحصول على تعليمات التصريف المناسبة.)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>التحضير</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>أخرج</strong><strong> </strong><strong>قلم الحقن مسبق التعبئة (ذاتي الحقن)</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>انزع</strong><strong> </strong><strong>الغطاء</strong><strong> </strong><strong>البلاستيكي</strong></p><p>&nbsp;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>أخرج</strong><strong> </strong><strong>الحقنة</strong><strong> </strong><strong>من</strong><strong> </strong><strong>العبوة</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>تحقّق</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>أختام</strong><strong> </strong><strong>الأمان</strong><strong> </strong><strong>ليست</strong><strong> </strong><strong>مكسورة</strong></p><p>&nbsp;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>أختام</strong><strong> </strong><strong>الأمان</strong></p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخرج علبة الكرتون من الثلاجة، وتأكد من أن أختام الأمان غير مكسورة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخرج العبوة من علبة الكرتون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انزع الغطاء البلاستيكي الشفاف من العبوة، بدءً من الزاوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمسك منتصف قلم الحقن مسبق التعبئة (ذاتي الحقن) (بالقرب من نافذة الفحص)، ثم أخرج بعناية قلم الحقن مسبق التعبئة (ذاتي الحقن) من العبوة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع قلم الحقن مسبق التعبئة (ذاتي الحقن) على سطح نظيف ومستوٍ، في درجة حرارة الغرفة، وبعيدًا عن أشعة الشمس المباشرة، وبعيدًا أيضًا عن متناول الأطفال.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تستخدم قلم الحقن مسبق التعبئة (ذاتي الحقن)إذا كان ختم الأمان الموجود على علبة الكرتون مكسورًا.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تزل غطاء الإبرة الرمادي خلال هذه الخطوة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>2.&nbsp;&nbsp;&nbsp; </strong><strong>تفحّص</strong><strong> </strong><strong>وانتظر</strong><strong> </strong><strong>مدة</strong><strong> </strong><strong>30</strong><strong> </strong><strong>دقيقة</strong><strong> </strong><strong>قبل</strong><strong> </strong><strong>الاستخدام</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>تفحّص</strong><strong> </strong><strong>تاريخ</strong><strong> </strong><strong>انتهاء</strong><strong> </strong><strong>الصلاحية</strong><strong> </strong><strong>والدواء</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>تاريخ</strong><strong> </strong><strong>انتهاء</strong><strong> </strong><strong>الصلاحية</strong><strong>: </strong><strong>شهر</strong><strong> </strong><strong>&ndash; </strong><strong>سنة</strong></p><p>&nbsp;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>انتظر</strong><strong>30</strong><strong> دقيقة</strong></p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأكد من عدم انقضاء تاريخ انتهاء الصلاحية المدوّن على الملصق الموجود على قلم الحقن مسبق التعبئة (ذاتي الحقن).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انظر إلى الدواء من خلال نافذة الفحص. يجب أن يتراوح لونه من الأصفر الشاحب إلى البني الشاحب، ولا يكون متعكّرًا، ولا يحتوي على جزيئات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من الطبيعي أن ترى فقاعة هواء واحدة أو أكثر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتظر لمدة 30 دقيقة (ولا تزد عن 8 ساعات) قبل الاستخدام.</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>لا</strong> تستخدمه إذا انقضى تاريخ الصلاحية.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تُسخّن قلم الحقن مسبق التعبئة (ذاتي الحقن) الخاص بك في الميكروويف، أو بالماء الساخن، أو تحت ضوء الشمس مباشرة.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong><strong> </strong>تستخدمه إذا كان الدواء يبدو عكرًا، أو متغيّر اللون، أو يحتوي على جزيئات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تستخدم قلم الحقن مسبق التعبئة (ذاتي الحقن) إذا تُرك خارج علبة الكرتون لأكثر من 8 ساعات.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>3.&nbsp;&nbsp;&nbsp; </strong><strong>حدّد موضع الحقن</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك أن تجري الحقن سواء في منطقة الفخذ أو البطن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعطي الحقنة لشخص آخر باعتبارك القائم بالرعاية أو مقدم الرعاية الصحية، يمكنك أيضًا أن إعطاء الحقن في الجزء العلوي من ذراع المريض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بحاجة إلى أكثر من حقنة واحدة لإكمال جرعتك، فاترك ما لا يقل عن 5 سنتيمترات بين كل موضع حقنة وآخر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تحقن الدواء في المناطق التي يحتوي فيها الجلد على كدمات، أو يكون رقيقًا، أو مُحمرًا، أو صلبًا.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تحقن في موضع قريب من السرّة بمسافة 5 سنتيمترات.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>4.&nbsp;&nbsp;&nbsp; </strong><strong>نظف </strong><strong>موضع الحقن</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اغسل يديك بالماء والصابون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نظف<strong> </strong>موضع الحقن مستخدمًا مسحة كحول، ثم دعه يجف في الهواء.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تلمس موضع الحقن المعقّم مرة أخرى حتى تُكمل الحقن.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الحقن</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>5.&nbsp;&nbsp;&nbsp; </strong><strong>أزل غطاء الإبرة </strong><strong>الشفاف</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزل غطاء الإبرة الشفاف من قلم الحقن مسبق التعبئة (ذاتي الحقن)، عن طريق سحبه مباشرة، بعيدًا عن واقِ الإبرة الأصفر (كما هو موضّح). قد تحتاج إلى استعمال القليل من القوة لإزالة غطاء الإبرة الشفاف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد ترى قطرة من الدواء في نهاية الإبرة. هذا أمر طبيعي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأكد من إجراء الحقن في غضون 5 دقائق من إزالة غطاء الإبرة الشفاف.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تضغط على واقِ الإبرة الأصفر باستخدام أصابعك. قد يؤدي هذا الأمر إلى تفعيل قلم الحقن مسبق التعبئة (ذاتي الحقن) في وقت مبكر جدًا، ويتسبب في جروح ناتجة عن وخز الإبرة.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تضع غطاء الإبرة الشفاف مرة أخرى على قلم الحقن مسبق التعبئة (ذاتي الحقن). قد يتسبب هذا الأمر في بدأ الحقن عن طريق الخطأ.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>6.&nbsp;&nbsp;&nbsp; </strong><strong>ابدأ الحقن</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>النقرة الأولى</strong></p></td></tr></tbody></table><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمسك قلم الحقن مسبق التعبئة (ذاتي الحقن) بحيث تكون نافذة الفحص مواجهة لك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع على قلم الحقن مسبق التعبئة (ذاتي الحقن) مباشرة على موضع الحقن، مع وضع واقِ الإبرة الأصفر مستويا على سطح جلدك، كما هو موضح.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للبدء في الحقن، ادفع المحقنة الذاتية كلها إلى الأسفل، واستمر في الضغط على المحقنة الذاتية على جلدك. بهذا، سينزلق واقِ الإبرة الأصفر نحو الأعلى داخل المحقنة الذاتية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي أن تسمع صوت أول نقرة، حتى تعرف أن الحقن قد بدأ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوف يتحرك المؤشر الأصفر نحو الأسفل من خلال نافذة الفحص عندما تتلقى جرعتك.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> ترفع المحقنة الذاتية في هذه الخطوة، لأن هذا الأمر قد يؤدي إلى حقن غير كامل.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تستخدم المحقنة الذاتية إذا كان واقِ الإبرة الأصفر لا ينزلق نحو الأعلى داخل المحقنة الذاتية. تخلّص منها في حاوية للتخلص من الأدوات الحادة.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تحاول استخدام المحقنة الذاتية مقلوبةً مع توجيه واقِ الإبرة الأصفر نحو الأعلى في مواجهة إبهامك.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>7.&nbsp;&nbsp;&nbsp; </strong><strong>أكمل الحقن</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>النقرة الثانية</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>استمر في الضغط نحو الأسفل وعدّ إلى الرقم 5، ثم ارفعها</strong></p></td></tr></tbody></table><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يستغرق الحقن حوالي 15 ثانية لإكماله.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استمر في الضغط على المحقنة الذاتية نحو الأسفل، حتى تسمع النقرة الثانية، وتتوقّف السدادة عن الحركة، ويغطي المؤشر الأصفر نافذة الفحص.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد سماع النقرة الثانية، استمر في الضغط، وعدّ إلى الرقم 5 قبل أن ترفع المحقنة الذاتية بعيدًا عن جلدك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تسمع النقرة الثانية:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحقق من أن المؤشر الأصفر يغطي نافذة الفحص، أو</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استمر في الضغط على المحقنة الذاتية نحو الأسفل، لمدة 15 ثانية لتتأكد من اكتمال الحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تكون هناك قطرة صغيرة من الدم في موضع الحقن. هذا أمر طبيعي. اضغط على المنطقة باستخدام قطعة من القطن أو ضمادة من الشاش، ثم ضع ضمادة لاصقة إذا احتجت إلى ذلك.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> ترفع المحقنة الذاتية حتى تسمع النقرة الثانية، ويغطي المؤشر الأصفر نافذة الفحص، وتكون قد أكملت العدّ إلى الرقم 5.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تفرك موضع الحقن.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تضع غطاء الإبرة الشفاف مرة أخرى على المحقنة الذاتية.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>التصريف</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>8.&nbsp;&nbsp;&nbsp; </strong><strong>تخلّص</strong><strong> </strong><strong>من</strong><strong> </strong><strong>قلم للحقن مسبق التعبئة (المحقنة</strong><strong> </strong><strong>الذاتية)</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>حاوية التخلص من الأدوات الحادة</strong></p></td></tr></tbody></table><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ضع المحقنة الذاتية المستعملة وغطاء الإبرة الشفاف في حاوية للتخلص من الأدوات الحادة، على الفور بعد الاستخدام.</p><p dir="RTL">إذا لم يكن لديك حاوية للتخلص من الأدوات الحادة، يمكنك استخدام حاوية منزلية، والتي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكون مصنوعةً من مادة بلاستيكية متينة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن إغلاقها بغطاء محكم، وغير قابلة للثقب، مع عدم إمكانية خروج الأدوات الحادة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ومستوية ومستقرة أثناء الاستخدام،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ومانعة للتسرب، و</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحمل ملصق موضوع بشكل صحيح للتحذير من النفايات الخطرة الموجودة داخلها.</p><p dir="RTL">عندما تكون حاوية التخلص من الأدوات الحادة ممتلئة تقريبًا، ستحتاج إلى اتباع المبادئ التوجيهية المجتمعية لمعرفة الطريقة الصحيحة للتخلص منها. قد تكون هناك قوانين المحافظة أو قوانين محلية حول كيفية التخلص من المحاقن الذاتية المستعملة.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تتخلص من حاوية التخلص الخاصة بالأدوات الحادة المستعملة، في صندوق القمامة المنزلية ما لم تسمح المبادئ التوجيهية المجتمعية بذلك.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong><strong> </strong>تُجري إعادة تدوير لحاوية التخلص من الأدوات الحادة المستعملة الخاصة بك.</p><p dir="RTL"><strong>احتفظ</strong><strong> </strong><strong>بحاوية</strong><strong> </strong><strong>التخلص</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الأدوات</strong><strong> </strong><strong>الحادة</strong><strong> </strong><strong>الخاصة</strong><strong> </strong><strong>بك</strong><strong> </strong><strong>بعيدًا</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>متناول</strong><strong> </strong><strong>الأطفال</strong><strong>.</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الأسئلة</strong><strong> </strong><strong>الشائعة المتداولة</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>هل</strong><strong> </strong><strong>يمكنني</strong><strong> </strong><strong>تغيير</strong><strong> </strong><strong>موضع</strong><strong> </strong><strong>الحقن</strong><strong> (</strong><strong>التناوب</strong><strong> </strong><strong>بين</strong><strong> </strong><strong>مواضع</strong><strong> </strong><strong>الحقن</strong><strong>) </strong><strong>الخاص</strong><strong> </strong><strong>بقلم الحقن مسبق التعبئة (ذاتي الحقن)؟</strong></p><p dir="RTL">يمكنك تغيير الموضع (التناوب بين مواضع الحقن) (سواء الفخذ، أو البطن، أو الجزء العلوي من الذراع)، أو تحريك المحقنة الذاتية، طالما أنك لم تبدأ في الضغط نحو الأسفل. حينما يُضغط واقِ الإبرة الأصفر، سيبدأ إجراء الحقن على الفور.</p><p dir="RTL"><strong>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>لماذا</strong><strong> </strong><strong>أحتاج</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>إجراء</strong><strong> </strong><strong>الحقن</strong><strong> </strong><strong>في</strong><strong> </strong><strong>غضون</strong><strong> 5 </strong><strong>دقائق</strong><strong> </strong><strong>من</strong><strong> </strong><strong>إزالة</strong><strong> </strong><strong>غطاء</strong><strong> </strong><strong>الإبرة</strong><strong> </strong><strong>الشفاف؟</strong></p><p dir="RTL">لأن هذا يمنع من أن يجفّ الدواء داخل الإبرة. إذ يمكن أن يؤثر ذلك على مقدار الدواء الذي تحصل عليه.</p><p dir="RTL"><strong>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ماذا</strong><strong> </strong><strong>يحدث</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>أزلت</strong><strong> </strong><strong>المحقنة</strong><strong> </strong><strong>الذاتية</strong><strong> </strong><strong>قبل</strong><strong> </strong><strong>سماع</strong><strong> </strong><strong>النقرة</strong><strong> </strong><strong>الثانية،</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>توقف</strong><strong> </strong><strong>السدادة</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>الحركة،</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>لم</strong><strong> </strong><strong>يكن</strong><strong> </strong><strong>المؤشر</strong><strong> </strong><strong>الأصفر</strong><strong> </strong><strong>قد</strong><strong> </strong><strong>غطّى</strong><strong> </strong><strong>نافذة</strong><strong> </strong><strong>الفحص؟</strong></p><p dir="RTL">إذا حدث هذا الأمر، فمن الممكن ألا تكون قد تلقيت جرعتك كاملة.</p><p dir="RTL"><strong>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>بمن</strong><strong> </strong><strong>أتصل</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>احتجت</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>المساعدة</strong><strong> </strong><strong>لتلقي</strong><strong> </strong><strong>الحقنة؟</strong></p><p dir="RTL">سيتمكن مقدم الرعاية الصحية من مساعدتك في أي أسئلة أخرى قد تكون لديك.</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تصنيع:</strong></p><p dir="RTL">جلاكسو أوپاريشنز المملكة المتحدة المحدودة*، بارنارد كاسل، المملكة المتحدة</p><p dir="RTL"><strong>الشركة المالكة لرخصة التسويق</strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة*، جدة، السعودية</p><p dir="RTL">* عضو مجموعة شركات جلاكسوسميث كلاين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوكالا علامة تجارية مملوكة أو مرخصة لمجموعة شركات جلاكسو سميث كلاين.
© 2021 جلاكسو سميث كلاين، جميع الحقوق محفوظة.

نص رقم: US version 29-07-2021
تاريخ الإصدار: 29 يوليو 2021 


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 This medicine is subject to additional monitoring. This will allow quick identification of
new safety information. You can help by reporting any side affects you may get. See Section 4 for how to report side effects.

NUCALA, solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                A clear to opalescent, colourless to pale yellow to pale brown solution in a single-use, pre-filled pen or syringe.
Each pre-filled syringe (safety-syringe) delivers 100 mg mepolizumab in 1 mL (100 mg/mL).
Each pre-filled pen (auto-injector) delivers 100 mg mepolizumab in 1 mL (100 mg/mL).
Mepolizumab is a humanised monoclonal antibody (IgG1, kappa), directed against human interleukin 5 (IL 5) produced in Chinese hamster ovary cells by recombinant DNA technology.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection in a pre-filled pen (auto-injector)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Maintenance Treatment of Severe Asthma</strong></p><p>NUCALA is indicated for the add-on maintenance treatment of adult and adolescents aged 12 years and older with severe asthma and with an eosinophilic phenotype [see <em>Posology and method of administration</em> and <em>Clinical Studies</em>].</p><p><strong>Limitations of Use</strong></p><p>NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Maintenance Treatment of Chronic Rhinosinusitis with Nasal Polyps</strong></p><p>NUCALA is indicated for the add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.</p><p><strong>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Eosinophilic Granulomatosis with Polyangiitis</strong></p><p>NUCALA is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).</p><p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Hypereosinophilic Syndrome</strong></p><p>NUCALA is indicated for the treatment of adult and adolescents patients aged 12 years and older with hypereosinophilic syndrome (HES) for &sup3;6 months without an identifiable non-hematologic secondary cause.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NUCALA is for subcutaneous use only.</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe Asthma</p><p><u>Adults and Adolescents Aged 12 Years and Older</u></p><p>The recommended dosage of NUCALA in adults and adolescents aged 12 years and older is 100&nbsp;mg administered once every 4 weeks by subcutaneous injection into the upper arm, thigh, or abdomen <em>[see Preparation and Administration of NUCALA Injection Prefilled Autoinjector and Prefilled Syringe]</em>.</p><p><u>Pediatric population:</u></p><p>The safety and effectiveness in pediatric patients aged younger than 6 years with severe asthma have not been established.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chronic Rhinosinusitis with Nasal Polyps</p><p>The recommended dosage of NUCALA is 100 mg administered once every 4 weeks by subcutaneous injection into the upper arm, thigh, or abdomen [<em>see Preparation and Administration of NUCALA Injection Prefilled Autoinjector and Prefilled Syringe</em>].</p><p><u>Paediatric Population</u></p><p>The safety and effectiveness in patients aged younger than 18 years with CRSwNP have not been established.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eosinophilic Granulomatosis with Polyangiitis</p><p>The recommended dosage of NUCALA is 300 mg administered once every 4 weeks by subcutaneous injection as 3 separate 100-mg injections into the upper arm, thigh, or abdomen <em>[see Preparation and Administration of NUCALA Injection Prefilled Autoinjector and Prefilled Syringe]</em>. Administer individual 100-mg injections at least 5 cm (approximately 2 inches) apart.</p><p><u>Paediatric Population</u></p><p>The safety and effectiveness in patients aged younger than 18 years with EGPA have not been established.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypereosinophilic Syndrome</p><p>The recommended dosage of NUCALA is 300 mg administered once every 4 weeks by subcutaneous injection as 3 separate 100-mg injections into the upper arm, thigh, or abdomen</p><p><em>[see Preparation and Administration of NUCALA Injection Prefilled Autoinjector and Prefilled Syringe]</em>. Administer individual 100-mg injections at least 5 cm (approximately 2 inches) apart.</p><p><u>Paediatric Population</u></p><p>The safety and effectiveness of NUCALA for HES have been established in adolescent patients aged 12 years and older. The safety and effectiveness in pediatric patients aged younger than 12&nbsp;years with HES have not been established.</p><p>Use of NUCALA for this indication is supported by evidence from an adequate and well‑controlled study (NCT02836496) in adults and adolescents and an open-label extension study (NCT03306043). One adolescent received NUCALA during the controlled study and this patient and an additional 3 adolescents received NUCALA during the open-label extension study <em>[see Clinical Studies]</em>. The 1 adolescent treated with NUCALA in the 32-week trial did not have a HES flare or an adverse event reported. All adolescents received 300 mg of NUCALA for 20&nbsp;weeks in the open-label extension.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Preparation and Administration of NUCALA Injection Prefilled Autoinjector and Prefilled Syringe:</strong></p><p>NUCALA injection is intended for use under the guidance of a healthcare provider. The NUCALA injection prefilled autoinjector and prefilled syringe are only for use in adults and adolescents aged 12 years and older. A patient may self-inject, or the patient caregiver may administer NUCALA injection subcutaneously after the healthcare provider determines it is appropriate. Provide proper training in subcutaneous injection technique and on the preparation and administration of NUCALA injection prior to use according to the &ldquo;Instructions for Use&rdquo;.</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the prefilled autoinjector or prefilled syringe from the refrigerator and allow it to sit at room temperature for 30&nbsp;minutes prior to injection. Do not warm NUCALA injection in any other way.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prior to administration, visually inspect the window of the prefilled autoinjector or the prefilled syringe for particulate matter or discoloration. NUCALA injection should be clear to opalescent, colorless to pale yellow to pale brown in color. Do not use NUCALA injection if the product exhibits discoloration, cloudiness, or particulate matter. Do not use the NUCALA prefilled autoinjector or prefilled syringe if dropped on a hard surface.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer the subcutaneous injection into the thigh or abdomen, avoiding the 5 cm (approximately 2&nbsp;inches) around the navel. The upper arm can also be used if a caregiver administers the subcutaneous injection.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For use in EGPA and HES, ensure injection sites for each subcutaneous injection are separated by at least 5&nbsp;cm (approximately 2 inches).</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Never give injections into areas where the skin is tender, bruised, red, or hard.</p><p>If a dose is missed, administer a dose as soon as possible. Thereafter, the patient can resume dosing on the usual day of administration. If the next dose is already due, then administer as planned.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NUCALA is contraindicated in patients with a history of hypersensitivity to mepolizumab or excipients in the formulation [see Special warnings and precautions for use, Pharmaceutical Particulars]. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity Reactions</u></p><p>Hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred following administration of NUCALA. These reactions generally occur within hours of administration, but in some instances can have a delayed onset (i.e., days). In the event of a hypersensitivity reaction, NUCALA should be discontinued <em>[see Contraindications]</em>.</p><p><u>Acute Asthma Symptoms or Deteriorating Disease</u></p><p>NUCALA should not be used to treat acute asthma symptoms or acute exacerbations. Do not use NUCALA to treat acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with NUCALA.</p><p><u>Opportunistic Infections: Herpes Zoster</u></p><p>Herpes zoster has occurred in subjects receiving NUCALA 100 mg in controlled clinical trials <em>[see Adverse Reactions]</em>. Consider vaccination if medically appropriate.<br />&nbsp;</p><p><u>Reduction of Corticosteroid Dosage</u></p><p>Do not discontinue systemic or inhaled corticosteroids (ICS) abruptly upon initiation of therapy with NUCALA. Reductions in corticosteroid dosage, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dosage may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.</p><p><u>Parasitic (Helminth) Infection</u></p><p>Eosinophils may be involved in the immunological response to some helminth infections. Patients with known parasitic infections were excluded from participation in clinical trials. It is unknown if NUCALA will influence a patient&rsquo;s response against parasitic infections. Treat patients with pre-existing helminth infections before initiating therapy with NUCALA. If patients become infected while receiving treatment with NUCALA and do not respond to anti‑helminth treatment, discontinue treatment with NUCALA until infection resolves.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Formal drug interaction trials have not been performed with NUCALA.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p><u>Risk Summary</u></p><p>The data on pregnancy exposure are insufficient to inform on drug-associated risk. Monoclonal antibodies, such as mepolizumab, are transported across the placenta in a linear fashion as pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimester of pregnancy. In a prenatal and postnatal development study conducted in cynomolgus monkeys, there was no evidence of fetal harm with IV administration of mepolizumab throughout pregnancy at doses that produced exposures up to approximately 9 times the exposure at the maximum recommended human dose (MRHD) of 300&nbsp;mg subcutaneous <em>(see Data)</em>.</p><p>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</p><p><u>Clinical Considerations</u></p><p><em>Disease-Associated Maternal and/or Embryofetal Risk:</em> In women with poorly or moderately controlled asthma, evidence demonstrates that there is an increased risk of preeclampsia in the mother and prematurity, low birth weight, and small for gestational age in the neonate. The level of asthma control should be closely monitored in pregnant women and treatment adjusted as necessary to maintain optimal control.</p><p><u>Data</u></p><p><em>Animal Data:</em> In a prenatal and postnatal development study, pregnant cynomolgus monkeys received mepolizumab from gestation Days 20 to 140 at doses that produced exposures up to approximately 9 times that achieved with the MRHD (on an AUC basis with maternal IV doses up to 100 mg/kg once every 4 weeks). Mepolizumab did not elicit adverse effects on fetal or neonatal growth (including immune function) up to 9 months after birth. Examinations for internal or skeletal malformations were not performed. Mepolizumab crossed the placenta in cynomolgus monkeys. Concentrations of mepolizumab were approximately 2.4 times higher in infants than in mothers up to Day 178 postpartum. Levels of mepolizumab in milk were &le;0.5% of maternal serum concentration.</p><p>In a fertility, early embryonic, and embryofetal development study, pregnant CD-1 mice received an analogous antibody, which inhibits the activity of murine interleukin-5 (IL-5), at an IV dose of 50&nbsp;mg/kg once per week throughout gestation. The analogous antibody was not teratogenic in mice. Embryofetal development of IL-5&ndash;deficient mice has been reported to be generally unaffected relative to wild-type mice.</p><p>Lactation</p><p>Risk Summary</p><p>There is no information regarding the presence of mepolizumab in human milk, the effects on the breastfed infant, or the effects on milk production. However, mepolizumab is a humanized monoclonal antibody (IgG1 kappa), and immunoglobulin G (IgG) is present in human milk in small amounts. Mepolizumab was present in the milk of cynomolgus monkeys postpartum following dosing during pregnancy [see <em>Pregnancy</em>]. The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for NUCALA and any potential adverse effects on the breastfed infant from mepolizumab or from the underlying maternal condition.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been no studies to investigate the effect of <em>NUCALA</em> on driving performance or the ability to operate machinery. A detrimental effect on such activities would not be anticipated from the pharmacology or adverse reaction profile of <em>NUCALA</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse Reactions</p><p>The following adverse reactions are described in greater detail in other sections:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity reactions <em>[see Special warnings and precautions for use]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Opportunistic infections: herpes zoster <em>[see Special warnings and precautions for use]</em></p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>4.8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical Studies Experience</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical Trials Experience in Severe Asthma</p><p><u>Adult and Adolescent Patients Aged 12 Years and Older</u></p><p>A total of 1,327 patients with severe asthma were evaluated in 3 randomized, placebo-controlled, multicenter trials of 24 to 52 weeks&rsquo; duration (Trial 1, NCT01000506; Trial 2, NCT01691521; and Trial 3, NCT01691508). Of these, 1,192 had a history of 2 or more exacerbations in the year prior to enrollment despite regular use of high-dose ICS plus additional controller(s) (Trials 1 and 2), and 135 patients required daily oral corticosteroids (OCS) in addition to regular use of high-dose ICS plus additional controller(s) to maintain asthma control (Trial 3). All patients had markers of eosinophilic airway inflammation <em>[see Clinical Studies]</em>. Of the patients enrolled, 59% were female, 85% were White, and ages ranged from 12 to 82 years. Mepolizumab was administered subcutaneously or intravenously once every 4 weeks; 263 patients received NUCALA (mepolizumab 100 mg subcutaneous) for at least 24&nbsp;weeks. Serious adverse events that occurred in more than 1 patient and in a greater percentage of patients receiving NUCALA 100&nbsp;mg (n&nbsp;=&nbsp;263) than placebo (n&nbsp;= 257) included 1 event, herpes zoster (2 patients vs. 0 patients, respectively). Approximately 2% of patients receiving NUCALA 100&nbsp;mg withdrew from clinical trials due to adverse events compared with 3% of patients receiving placebo.</p><p>The incidence of adverse reactions in the first 24 weeks of treatment in the 2 confirmatory efficacy and safety trials (Trials 2 and 3) with NUCALA 100&nbsp;mg is shown in Table&nbsp;1.</p><p><strong>Table 1. Adverse Reactions with NUCALA with &ge;3% Incidence and More Common than Placebo in Patients with Severe Asthma (Trials 2 and 3)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p><strong>Adverse Reaction</strong></p></td><td style="vertical-align:bottom"><p><strong>NUCALA</strong></p><p><strong>(Mepolizumab 100 mg Subcutaneous)</strong></p><p><strong>(n = 263)</strong></p><p><strong>%</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo</strong></p><p><strong>(n = 257)</strong></p><p><strong>%</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:bottom"><p>19</p></td><td style="vertical-align:bottom"><p>18</p></td></tr><tr><td style="vertical-align:top"><p>Injection site reaction</p></td><td style="vertical-align:bottom"><p>8</p></td><td style="vertical-align:bottom"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:bottom"><p>5</p></td><td style="vertical-align:bottom"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:bottom"><p>5</p></td><td style="vertical-align:bottom"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>Influenza</p></td><td style="vertical-align:bottom"><p>3</p></td><td style="vertical-align:bottom"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection</p></td><td style="vertical-align:bottom"><p>3</p></td><td style="vertical-align:bottom"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain upper</p></td><td style="vertical-align:bottom"><p>3</p></td><td style="vertical-align:bottom"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:bottom"><p>3</p></td><td style="vertical-align:bottom"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Eczema</p></td><td style="vertical-align:bottom"><p>3</p></td><td style="vertical-align:bottom"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p>Muscle spasms</p></td><td style="vertical-align:bottom"><p>3</p></td><td style="vertical-align:bottom"><p>&lt;1</p></td></tr></tbody></table><p><em>52-Week Trial:</em> Adverse reactions from Trial 1 with 52 weeks of treatment with mepolizumab 75&nbsp;mg intravenous (IV) (n = 153) or placebo (n = 155) and with &ge;3% incidence and more common than placebo and not shown in Table 1 were: abdominal pain, allergic rhinitis, asthenia, bronchitis, cystitis, dizziness, dyspnea, ear infection, gastroenteritis, lower respiratory tract infection, musculoskeletal pain, nasal congestion, nasopharyngitis, nausea, pharyngitis, pyrexia, rash, toothache, viral infection, viral respiratory tract infection, and vomiting. In addition, 3 cases of herpes zoster occurred in patients receiving mepolizumab 75 mg IV compared with 2 patients in the placebo group.</p><p><em>Systemic Reactions, including Hypersensitivity Reactions:</em> In Trials 1, 2, and 3 described above, the percentage of patients who experienced systemic (allergic and non-allergic) reactions was 3% in the group receiving NUCALA 100&nbsp;mg and 5% in the placebo group. Systemic allergic/hypersensitivity reactions were reported by 1% of patients in the group receiving NUCALA 100&nbsp;mg and 2% of patients in the placebo group. The most commonly reported manifestations of systemic allergic/hypersensitivity reactions reported in the group receiving NUCALA 100&nbsp;mg included rash, pruritus, headache, and myalgia. Systemic non-allergic reactions were reported by 2% of patients in the group receiving NUCALA 100&nbsp;mg and 3% of patients in the placebo group. The most commonly reported manifestations of systemic non‑allergic reactions reported in the group receiving NUCALA 100&nbsp;mg included rash, flushing, and myalgia. A majority of the systemic reactions in patients receiving NUCALA 100&nbsp;mg (5/7) were experienced on the day of dosing.</p><p><em>Injection Site Reactions:</em> Injection site reactions (e.g., pain, erythema, swelling, itching, burning sensation) occurred at a rate of 8% in patients receiving NUCALA 100&nbsp;mg compared with 3% in patients receiving placebo.</p><p><em>Long-term Safety:</em> Nine hundred ninety-eight patients received NUCALA 100&nbsp;mg in ongoing open-label extension studies, during which additional cases of herpes zoster were reported. The overall adverse event profile has been similar to the severe asthma trials described above.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical Trials Experience in Chronic Rhinosinusitis with Nasal Polyps</p><p>A total of 407 patients with CRSwNP were evaluated in 1 randomized, placebo-controlled, multicenter, 52-week treatment trial. Patients received NUCALA 100 mg or placebo subcutaneously once every 4 weeks. Patients had recurrent CRSwNP with a history of prior surgery and were on nasal corticosteroids for at least 8 weeks prior to screening <em>[see Clinical Studies]</em>. Of the patients enrolled, 35% were female, 93% were White, and ages ranged from 18 to 82 years. Approximately 2% of patients receiving NUCALA 100&nbsp;mg withdrew from study treatment due to adverse events compared with 2% of patients receiving placebo.</p><p>Table 2 summarizes adverse reactions that occurred in &ge; 3% of NUCALA-treated patients and more frequently than in patients treated with placebo in the CRSwNP trial.</p><p><strong>Table 2. Adverse Reactions with NUCALA with &ge;3% Incidence and More Common than Placebo in Patients with CRSwNP</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p><strong>Adverse Reaction</strong></p></td><td style="vertical-align:bottom"><p><strong>NUCALA</strong></p><p><strong>(Mepolizumab 100 mg Subcutaneous)</strong></p><p><strong>(n = 206)</strong></p><p><strong>%</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo</strong></p><p><strong>(n = 201)</strong></p><p><strong>%</strong></p></td></tr><tr><td style="vertical-align:top"><p>Oropharyngeal pain</p></td><td style="vertical-align:bottom"><p>8</p></td><td style="vertical-align:bottom"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:bottom"><p>6</p></td><td style="vertical-align:bottom"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal Pain Upper</p></td><td style="vertical-align:bottom"><p>3</p></td><td style="vertical-align:bottom"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:bottom"><p>3</p></td><td style="vertical-align:bottom"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:bottom"><p>3</p></td><td style="vertical-align:bottom"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Nasal dryness</p></td><td style="vertical-align:bottom"><p>3</p></td><td style="vertical-align:bottom"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:bottom"><p>3</p></td><td style="vertical-align:bottom"><p>&lt;1</p></td></tr></tbody></table><p>CRSwNP = Chronic Rhinosinusitis with Nasal Polyps.</p><p><u>Systemic Reactions, including Hypersensitivity Reactions</u></p><p>In the 52-week trial, the percentage of patients who experienced systemic (allergic [type I hypersensitivity] and other) reactions was &lt;1% in the group receiving NUCALA 100 mg and &lt;1% in the placebo group. Systemic allergic (type I hypersensitivity) reactions were reported by &lt;1% of patients in the group receiving NUCALA 100 mg and no patients in the placebo group. The manifestations of systemic allergic (type I hypersensitivity) reactions included urticaria, erythema, and rash and 1 of the 3 reactions occurred on the day of dosing. Other systemic reactions were reported by no patients in the group receiving NUCALA 100 mg and &lt;1% of patients in the placebo group.</p><p><u>Injection Site Reactions</u></p><p>Injection site reactions (e.g., erythema, pruritus) occurred at a rate of 2% in patients receiving NUCALA 100 mg compared with &lt;1% in patients receiving placebo.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical Trials Experience in Eosinophilic Granulomatosis with Polyangiitis</p><p>A total of 136 patients with EGPA were evaluated in 1 randomized, placebo-controlled, multicenter, 52-week treatment trial. Patients received 300&nbsp;mg of NUCALA or placebo subcutaneously once every 4 weeks. Patients enrolled had a diagnosis of EGPA for at least 6&nbsp;months prior to enrollment with a history of relapsing or refractory disease and were on a stable dosage of oral prednisolone or prednisone of greater than or equal to 7.5 mg/day (but not greater than 50 mg/day) for at least 4 weeks prior to enrollment <em>[see Clinical Studies]</em>. Of the patients enrolled, 59% were female, 92% were White, and ages ranged from 20 to 71&nbsp;years. No additional adverse reactions were identified to those reported in the severe asthma trials.</p><p><u>Systemic Reactions, including Hypersensitivity Reactions</u></p><p>In the 52-week trial, the percentage of patients who experienced systemic (allergic and non‑allergic) reactions was 6% in the group receiving 300 mg of NUCALA and 1% in the placebo group. Systemic allergic/hypersensitivity reactions were reported by 4% of patients in the group receiving 300&nbsp;mg of NUCALA and 1% of patients in the placebo group. The manifestations of systemic allergic/hypersensitivity reactions reported in the group receiving 300&nbsp;mg of NUCALA included rash, pruritus, flushing, fatigue, hypertension, warm sensation in trunk and neck, cold extremities, dyspnea, and stridor. Systemic non-allergic reactions were reported by 1 (1%) patient in the group receiving 300 mg of NUCALA and no patients in the placebo group. The reported manifestation of systemic non-allergic reactions reported in the group receiving 300 mg of NUCALA was angioedema. Half of the systemic reactions in patients receiving 300 mg of NUCALA (2/4) were experienced on the day of dosing.</p><p><u>Injection Site Reactions</u></p><p>Injection site reactions (e.g., pain, erythema, swelling) occurred at a rate of 15% in patients receiving 300 mg of NUCALA compared with 13% in patients receiving placebo.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical Trials Experience in Hypereosinophilic Syndrome</p><p>A total of 108 adult and adolescent patients aged 12 years and older with HES were evaluated in a randomized, placebo-controlled, multicenter, 32-week treatment trial. Patients with non-hematologic secondary HES or FIP1L1-PDGFR&alpha; kinase-positive HES were excluded from the trial. Patients received 300&nbsp;mg of NUCALA or placebo subcutaneously once every 4 weeks. Patients must have been on a stable dose of background HES therapy for the 4 weeks prior to randomization <em>[see Clinical Studies]</em>. Of the patients enrolled, 53% were female, 93% were White, and ages ranged from 12 to 82 years. No additional adverse reactions were identified to those reported in the severe asthma trials.</p><p><u>Systemic Reactions, including Hypersensitivity Reactions</u></p><p>In the trial, no systemic allergic (type I hypersensitivity) reactions were reported. Other systemic reactions were reported by 1 (2%) patient in the group receiving 300 mg of NUCALA and no patients in the placebo group. The reported manifestation of other systemic reaction was multifocal skin reaction experienced on the day of dosing.</p><p><u>Injection Site Reactions</u></p><p>Injection site reactions (e.g., burning, itching) occurred at a rate of 7% in patients receiving 300&nbsp;mg of NUCALA compared with 4% in patients receiving placebo.</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immunogenicity</p><p>In adult and adolescent patients with severe asthma receiving NUCALA 100&nbsp;mg, 15/260 (6%) had detectable anti-mepolizumab antibodies. Neutralizing antibodies were detected in 1 patient with asthma receiving NUCALA 100&nbsp;mg. Anti-mepolizumab antibodies slightly increased (approximately 20%) the clearance of mepolizumab. There was no evidence of a correlation between anti-mepolizumab antibody titers and change in eosinophil level. The clinical relevance of the presence of anti-mepolizumab antibodies is not known.</p><p>In patients with CRSwNP receiving NUCALA 100 mg, 6/196 (3%) had detectable anti‑mepolizumab antibodies. No neutralizing antibodies were detected in any patients with CRSwNP.</p><p>In patients with EGPA receiving 300&nbsp;mg of NUCALA, 1/68 (&lt;2%) had detectable anti‑mepolizumab antibodies. No neutralizing antibodies were detected in any patients with EGPA.</p><p>In adult and adolescent patients with HES receiving 300&nbsp;mg of NUCALA, 1/53 (2%) had detectable anti-mepolizumab antibodies. No neutralizing antibodies were detected in any patients with HES.</p><p>The reported frequency of anti-mepolizumab antibodies may underestimate the actual frequency due to lower assay sensitivity in the presence of high drug concentration. The data reflect the percentage of patients whose test results were positive for antibodies to mepolizumab in specific assays. The observed incidence of antibody positivity in an assay is highly dependent on several factors, including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.</p><p>4.8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Post-marketing Experience</p><p>In addition to adverse reactions reported from clinical trials, the following adverse reactions have been identified during post-approval use of NUCALA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, or causal connection to NUCALA or a combination of these factors.</p><p><u>Immune System Disorders</u></p><p>Hypersensitivity reactions, including anaphylaxis.</p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GlaxoSmithKline - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><ul><li>Mobile: +966-56-904-9882</li><li>Email: gcc.medinfo@gsk.com</li><li>Website: https://gskpro.com/en-sa/<u> </u></li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Centre: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa &nbsp;&nbsp;&nbsp;&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p><strong>-GlaxoSmithKline - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: <u>s</u>audi.safety@gsk.com &nbsp;</li><li>Website: https://gskpro.com/en-sa/</li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment for an overdose with mepolizumab. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>ATC code </strong></p><p>Pharmacotherapeutic group: Drugs for obstructive airway diseases, other systemic drugs for obstructive airway diseases</p><p>R03DX09</p><p><strong>Mechanism of Action</strong></p><p>Mepolizumab is an IL-5 antagonist (IgG1 kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Mepolizumab binds to IL-5 with a dissociation constant of 100 pM, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface. Inflammation is an important component in the pathogenesis of asthma, CRSwNP, EGPA, and HES. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in inflammation. Mepolizumab, by inhibiting IL-5 signaling, reduces the production and survival of eosinophils; however, the mechanism of mepolizumab action in asthma, CRSwNP, EGPA, and HES has not been definitively established.</p><p><strong>Pharmacodynamic effects</strong></p><p>The pharmacodynamic response (blood eosinophil reduction) following repeat doses of mepolizumab administered subcutaneously or intravenously was evaluated in adult subjects with asthma and blood eosinophil levels &gt;200 cells/mcL. Subjects received 1 of 4 mepolizumab treatments (administered every 28 days for a total of 3 doses): 12.5 mg subcutaneous, 125 mg subcutaneous, 250 mg subcutaneous, or 75 mg IV. Sixty-six of the 70 randomized subjects completed the trial. Compared with baseline levels, blood eosinophils decreased in a dose‑dependent manner. A reduction in blood eosinophil levels was observed in all treatment groups by Day 3 (48 hours post-dose). On Day 84 (4 weeks post-last dose), the observed geometric mean reduction from baseline in blood eosinophils was 64%, 78%, 84%, and 90% in the 12.5-mg subcutaneous, 75-mg IV, 125-mg subcutaneous, and 250‑mg subcutaneous treatment groups, respectively. The model-predicted subcutaneous doses providing 50% and 90% of maximal reduction of blood eosinophils at Day 84 were estimated to be 11 and 99 mg, respectively. These results, along with the clinical efficacy data from the dose-ranging exacerbation trial in adult and adolescent subjects with severe asthma (Trial 1) supported the evaluation of mepolizumab 75 mg IV and 100 mg subcutaneous in the confirmatory severe asthma trials <em>[see Clinical Studies]</em>. Following subcutaneous administration of mepolizumab 100 mg every 4 weeks for 32 weeks in adult and adolescent subjects with severe asthma (Trial 2), blood eosinophils were reduced to a geometric mean count of 40 cells/mcL, which corresponds to a geometric mean reduction of 84% compared with placebo.</p><p>The magnitude of reduction in adults and adolescents was observed within 4 weeks of treatment and was maintained throughout the treatment periods.</p><p>For adults with CRSwNP, following subcutaneous administration of mepolizumab 100 mg every 4 weeks for 52 weeks, blood eosinophils were reduced to a geometric mean count of 60&nbsp;cells/mcL. There was a geometric mean reduction of 83% compared with placebo. This magnitude of reduction was observed within 4 weeks of treatment and was maintained throughout the treatment period<em> [see Clinical Studies]</em>.</p><p>For adults with EGPA, following subcutaneous administration of mepolizumab 300 mg every 4&nbsp;weeks for 52 weeks, blood eosinophils were reduced to a geometric mean count of 38 cells/mcL. There was a geometric mean reduction of 83% compared with placebo, and this magnitude of reduction was observed within 4 weeks of treatment<em> [see Clinical Studies]</em>.</p><p>For adults and adolescents with HES, following subcutaneous administration of mepolizumab 300&nbsp;mg every 4 weeks for 32&nbsp;weeks, blood eosinophils were reduced to a geometric mean count of 70&nbsp;cells/mcL. There was a geometric mean reduction of 92% compared with placebo<em> [see Clinical Studies]</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following subcutaneous dosing in adult subjects with asthma, mepolizumab exhibited approximately dose‑proportional pharmacokinetics over a dose range of 12.5 to 250 mg. The pharmacokinetic properties of mepolizumab observed in subjects with CRSwNP (adults), EGPA (adults) or HES (adults and adolescents) were similar to the pharmacokinetic properties observed in subjects with severe asthma (adults and adolescents).</p><p>Subcutaneous administration of mepolizumab 300&nbsp;mg had approximately 3&nbsp;times the systemic exposure of mepolizumab 100&nbsp;mg.</p><p><strong>Absorption</strong></p><p>Following 100-mg subcutaneous administration in the upper arm of adult and adolescent subjects with asthma, the bioavailability of mepolizumab was estimated to be approximately 80%.</p><p>Following repeat subcutaneous administration once every 4 weeks, there was approximately a 2‑fold accumulation at steady state.</p><p><strong>Distribution</strong></p><p>The population central volume of distribution of mepolizumab in adult subjects with asthma is estimated to be 3.6&nbsp;L for a 70-kg individual.</p><p><strong>Elimination</strong></p><p>Following subcutaneous administration of mepolizumab in adult subjects with asthma, the mean terminal half‑life (t<sub>1/2</sub>) ranged from 16 to 22 days. The population apparent systemic clearance of mepolizumab in adult and adolescent subjects with asthma is estimated to be 0.28&nbsp;L/day for a 70-kg individual.</p><p><em>Metabolism: </em>Mepolizumab is a humanized IgG1 monoclonal antibody that is degraded by the proteolytic enzymes widely distributed in the body and not restricted to hepatic tissue.</p><p><strong>Specific Populations</strong></p><p><em>Racial Groups and Male and Female Patients:</em> Population pharmacokinetics analyses indicated there was no significant effect of race and gender on mepolizumab clearance.</p><p><em>Age:</em> Population pharmacokinetics analyses indicated there was no significant effect of age on mepolizumab clearance.</p><p><em>Geriatric Patients: </em>Clinical trials of NUCALA did not include sufficient numbers of patients aged 65 years and older that received NUCALA (n&nbsp;=&nbsp;79) to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. Based on available data, no adjustment of the dosage of NUCALA in geriatric patients is necessary, but greater sensitivity in some older individuals cannot be ruled out.</p><p><em>Patients with Renal Impairment:</em> No clinical trials have been conducted to investigate the effect of renal impairment on the pharmacokinetics of mepolizumab. Based on population pharmacokinetic analyses, mepolizumab clearance was comparable between subjects with creatinine clearance values between 50 and 80&nbsp;mL/min and patients with normal renal function. There are limited data available in subjects with creatinine clearance values &lt;50&nbsp;mL/min; however, mepolizumab is not cleared renally.</p><p><em>Patients with Hepatic Impairment:</em> No clinical trials have been conducted to investigate the effect of hepatic impairment on the pharmacokinetics of mepolizumab. Since mepolizumab is degraded by widely distributed proteolytic enzymes, not restricted to hepatic tissue, changes in hepatic function are unlikely to have any effect on the elimination of mepolizumab.</p><p><strong>Drug Interaction Studies</strong></p><p>No formal drug interaction studies have been conducted with mepolizumab. In population pharmacokinetics analyses of Phase 3 studies, there was no evidence of an effect of commonly co-administered small molecule drugs on mepolizumab exposure.</p><p><u>CLINICAL STUDIES</u></p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe Asthma</p><p>The asthma development program for NUCALA in patients aged 12 years and older included 3 double-blind, randomized, placebo‑controlled trials: 1 dose-ranging and exacerbation trial (Trial&nbsp;1, NCT01000506) and 2 confirmatory trials (Trial 2, NCT01691521 and Trial 3, NCT01691508). Mepolizumab was administered every 4&nbsp;weeks in all 3 trials as add-on to background treatment. All patients continued their background asthma therapy throughout the duration of the trials.</p><p><u>Dose-Ranging and Exacerbation Trial</u></p><p>Trial 1 was a 52-week dose-ranging and exacerbation-reduction trial in patients with severe asthma with a history of 2 or more exacerbations in the previous year despite regular use of high‑dose ICS plus additional controller(s) with or without OCS. Patients enrolled in this trial were required to have at least 1 of the following 4 pre-specified criteria in the previous 12&nbsp;months: blood eosinophil count &ge;300&nbsp;cells/mcL, sputum eosinophil count &ge;3%, exhaled nitric oxide concentration &ge;50 ppb, or deterioration of asthma control after &le;25% reduction in regular maintenance ICS/OCS. Three IV dosages of mepolizumab (75, 250, and 750 mg) administered once every 4 weeks were evaluated compared with placebo. Results from this trial and the pharmacodynamic study supported the evaluation of mepolizumab 75 mg IV and 100 mg subcutaneous in the subsequent trials <em>[see Pharmacological Properties]</em>. NUCALA is not indicated for IV use and should only be administered by the subcutaneous route.</p><p><u>Confirmatory Trials</u></p><p>A total of 711 patients with severe asthma were studied in the 2 confirmatory trials (Trials 2 and 3). In these 2 trials patients were required to have blood eosinophils of &ge;150&nbsp;cells/mcL at screening (within 6 weeks of dosing) or blood eosinophils of &ge;300 cells/mcL within 12 months of enrollment. The screening blood eosinophils of &ge;150 cells/mcL criterion was derived from exploratory analyses of data from Trial 1. Trial 2 was a 32-week placebo- and active-controlled trial in patients with severe asthma with a history of 2 or more exacerbations in the previous year despite regular use of high-dose ICS plus additional controller(s) with or without OCS. Patients received mepolizumab 75 mg IV (n&nbsp;=&nbsp;191), NUCALA 100&nbsp;mg (n&nbsp;=&nbsp;194), or placebo (n&nbsp;=&nbsp;191) once every 4 weeks for 32 weeks.</p><p>Trial 3 was a 24-week OCS-reduction trial in patients with severe asthma who required daily OCS in addition to regular use of high-dose ICS plus additional controller(s) to maintain asthma control. Patients in Trial 3 were not required to have a history of exacerbations in the previous year. Patients received NUCALA 100&nbsp;mg (n&nbsp;=&nbsp;69) or placebo (n&nbsp;=&nbsp;66) once every 4 weeks for 24&nbsp;weeks. The baseline mean OCS use was similar in the 2 treatment groups: 13.2 mg in the placebo group and 12.4 mg in the group receiving NUCALA 100&nbsp;mg.</p><p>The demographics and baseline characteristics of these 3 trials are provided in Table&nbsp;3.</p><p><strong>Table 3. Demographics and Baseline Characteristics of Severe Asthma Trials</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:bottom"><p><strong>Trial 1</strong></p><p><strong>(N = 616)</strong></p></td><td style="vertical-align:bottom"><p><strong>Trial 2</strong></p><p><strong>(N = 576)</strong></p></td><td style="vertical-align:bottom"><p><strong>Trial 3</strong></p><p><strong>(N = 135)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean age, years</p></td><td style="vertical-align:top"><p>49</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p>Female, n (%)</p></td><td style="vertical-align:top"><p>387 (63)</p></td><td style="vertical-align:top"><p>328 (57)</p></td><td style="vertical-align:top"><p>74 (55)</p></td></tr><tr><td style="vertical-align:top"><p>White, n (%)</p></td><td style="vertical-align:top"><p>554 (90)</p></td><td style="vertical-align:top"><p>450 (78)</p></td><td style="vertical-align:top"><p>128 (95)</p></td></tr><tr><td style="vertical-align:top"><p>Duration of asthma, years, mean</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>19</p></td></tr><tr><td style="vertical-align:top"><p>Never smoked, n (%)</p></td><td style="vertical-align:top"><p>483 (78)</p></td><td style="vertical-align:top"><p>417 (72)</p></td><td style="vertical-align:top"><p>82 (61)</p></td></tr><tr><td style="vertical-align:top"><p>Baseline FEV<sub>1</sub>, L</p></td><td style="vertical-align:top"><p>1.88</p></td><td style="vertical-align:top"><p>1.82</p></td><td style="vertical-align:top"><p>1.95</p></td></tr><tr><td style="vertical-align:top"><p>Baseline % predicted FEV<sub>1</sub></p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>59</p></td></tr><tr><td style="vertical-align:top"><p>Baseline % reversibility</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>26</p></td></tr><tr><td style="vertical-align:top"><p>Baseline post-SABA FEV<sub>1</sub>/FVC</p></td><td style="vertical-align:top"><p>0.67</p></td><td style="vertical-align:top"><p>0.66</p></td><td style="vertical-align:top"><p>0.66</p></td></tr><tr><td style="vertical-align:top"><p>Geometric mean eosinophil count at baseline, cells/mcL</p></td><td style="vertical-align:top"><p>250</p></td><td style="vertical-align:top"><p>290</p></td><td style="vertical-align:top"><p>240</p></td></tr><tr><td style="vertical-align:top"><p>Mean number of exacerbations in previous year</p></td><td style="vertical-align:top"><p>3.6</p></td><td style="vertical-align:top"><p>3.6</p></td><td style="vertical-align:top"><p>3.1</p></td></tr></tbody></table><p>FEV<sub>1</sub> = forced expiratory volume in 1 second, SABA = short-acting beta<sub>2</sub>-agonist, FVC = forced vital capacity.</p><p><u>Exacerbations</u></p><p>Efficacy was assessed in Trials 1 and 2 using an endpoint of the frequency of exacerbations defined as worsening of asthma requiring use of oral/systemic corticosteroids and/or hospitalization and/or emergency department visits. For patients on maintenance OCS, an exacerbation requiring OCS was defined as the use of oral/systemic corticosteroids at least double the existing dose for at least 3 days. Compared with placebo, patients receiving NUCALA 100&nbsp;mg or mepolizumab 75&nbsp;mg IV experienced significantly fewer exacerbations. Additionally, compared with placebo, there were fewer exacerbations requiring hospitalization and/or emergency department visits and exacerbations requiring only in-patient hospitalization with NUCALA 100&nbsp;mg (Table 4).</p><p><strong>Table 4. Rate of Exacerbations in Severe Asthma Trials 1 and 2 (Intent-to-Treat Population)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Trial</strong></p></td><td rowspan="2" style="vertical-align:bottom"><p><strong>Treatment</strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Exacerbations per Year</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Rate</strong></p></td><td style="vertical-align:bottom"><p><strong>Difference</strong></p></td><td style="vertical-align:bottom"><p><strong>Rate Ratio</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td colspan="5" style="vertical-align:bottom"><p><strong>All exacerbations</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Trial 1</p></td><td style="vertical-align:bottom"><p>Placebo (n = 155)</p></td><td style="vertical-align:bottom"><p>2.40</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mepolizumab 75 mg IV (n = 153)</p></td><td style="vertical-align:top"><p>1.24</p></td><td style="vertical-align:top"><p>1.16</p></td><td style="vertical-align:bottom"><p>0.52</p><p>(0.39, 0.69)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Trial 2</p></td><td style="vertical-align:bottom"><p>Placebo (n = 191)</p></td><td style="vertical-align:bottom"><p>1.74</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mepolizumab 75 mg IV (n = 191)</p></td><td style="vertical-align:top"><p>0.93</p></td><td style="vertical-align:top"><p>0.81</p></td><td style="vertical-align:bottom"><p>0.53</p><p>(0.40, 0.72)</p></td></tr><tr><td style="vertical-align:top"><p>NUCALA 100 mg SC (n = 194)</p></td><td style="vertical-align:top"><p>0.83</p></td><td style="vertical-align:top"><p>0.91</p></td><td style="vertical-align:bottom"><p>0.47</p><p>(0.35, 0.64)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Exacerbations requiring hospitalization/emergency room visit</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Trial 1</p></td><td style="vertical-align:bottom"><p>Placebo (n = 155)</p></td><td style="vertical-align:bottom"><p>0.43</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mepolizumab 75 mg IV (n = 153)</p></td><td style="vertical-align:top"><p>0.17</p></td><td style="vertical-align:top"><p>0.26</p></td><td style="vertical-align:bottom"><p>0.40</p><p>(0.19, 0.81)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Trial 2</p></td><td style="vertical-align:bottom"><p>Placebo (n = 191)</p></td><td style="vertical-align:bottom"><p>0.20</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mepolizumab 75 mg IV (n = 191)</p></td><td style="vertical-align:top"><p>0.14</p></td><td style="vertical-align:top"><p>0.06</p></td><td style="vertical-align:bottom"><p>0.68</p><p>(0.33, 1.41)</p></td></tr><tr><td style="vertical-align:top"><p>NUCALA 100 mg SC (n = 194)</p></td><td style="vertical-align:top"><p>0.08</p></td><td style="vertical-align:top"><p>0.12</p></td><td style="vertical-align:bottom"><p>0.39</p><p>(0.18, 0.83)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Exacerbations requiring hospitalization</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Trial 1</p></td><td style="vertical-align:bottom"><p>Placebo (n = 155)</p></td><td style="vertical-align:bottom"><p>0.18</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mepolizumab 75 mg IV (n = 153)</p></td><td style="vertical-align:top"><p>0.11</p></td><td style="vertical-align:top"><p>0.07</p></td><td style="vertical-align:bottom"><p>0.61</p><p>(0.28, 1.33)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Trial 2</p></td><td style="vertical-align:bottom"><p>Placebo (n = 191)</p></td><td style="vertical-align:bottom"><p>0.10</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mepolizumab 75 mg IV (n = 191)</p></td><td style="vertical-align:top"><p>0.06</p></td><td style="vertical-align:top"><p>0.04</p></td><td style="vertical-align:bottom"><p>0.61</p><p>(0.23, 1.66)</p></td></tr><tr><td style="vertical-align:top"><p>NUCALA 100 mg SC (n = 194)</p></td><td style="vertical-align:top"><p>0.03</p></td><td style="vertical-align:top"><p>0.07</p></td><td style="vertical-align:bottom"><p>0.31</p><p>(0.11, 0.91)</p></td></tr></tbody></table><p>IV&nbsp;=&nbsp;intravenous, SC&nbsp;=&nbsp;subcutaneous, CI&deg;=&deg;Confidence Interval.</p><p>The time to first exacerbation was longer for the groups receiving NUCALA 100&nbsp;mg and mepolizumab 75 mg IV compared with placebo in Trial 2 (Figure&nbsp;1).</p><p><strong>Figure 1. Kaplan-Meier Cumulative Incidence Curve for Time to First Exacerbation (Severe Asthma Trial 2)</strong></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_13" o:spid="_x0000_i1028" type="#_x0000_t75"
 style='width:451.5pt;height:186.75pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="602" height="249" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p><p>IV&nbsp;=&nbsp;intravenous, SC&nbsp;=&nbsp;subcutaneous.</p><p>Trial 1 data were explored to determine criteria that could identify patients likely to benefit from treatment with NUCALA. The exploratory analysis suggested that baseline blood eosinophil count of &ge;150 cells/mcL was a potential predictor of treatment benefit. Exploratory analysis of Trial 2 data also suggested that baseline blood eosinophil count (obtained within 6&nbsp;weeks of initiation of dosing) of &ge;150 cells/mcL was a potential predictor of efficacy and showed a trend of greater exacerbation benefit with increasing blood eosinophil count. In Trial 2, patients enrolled solely on the basis of the historical blood eosinophil count of &ge;300&nbsp;cells/mcL in the previous 12&nbsp;months, but who had a baseline blood eosinophil count &lt;150 cells/mcL, had virtually no exacerbation benefit following treatment with NUCALA 100&nbsp;mg compared with placebo.</p><p>The Asthma Control Questionnaire-5 (ACQ-5) was assessed in Trials 1 and 2, and the St. George&rsquo;s Respiratory Questionnaire (SGRQ) was assessed in Trial 2. In Trial 1, the ACQ-5 responder rate (defined as a decrease in score of 0.5 or more as threshold) for the 75-mg IV mepolizumab arm was 47% compared with 50% for placebo with an odds ratio (OR) of 1.1 (95%&nbsp;CI: 0.7, 1.7). In Trial 2, the ACQ-5 responder rate for the treatment arm for NUCALA 100&nbsp;mg was 57% compared with 45% for placebo with an OR of 1.8 (95%&nbsp;CI: 1.2, 2.8). In Trial 2, the SGRQ responder rate (defined as a decrease in score of 4 or more as threshold) for the treatment arm for NUCALA 100&nbsp;mg was 71% compared with 55% for placebo with an OR of 2.1 (95%&nbsp;CI: 1.3, 3.2).</p><p><u>Oral Corticosteroid Reduction</u></p><p>Trial 3 evaluated the effect of NUCALA 100&nbsp;mg on reducing the use of maintenance OCS. Efficacy was assessed using an endpoint of the percent reduction of OCS dose during Weeks 20 to 24 compared with baseline dose, while maintaining asthma control. Patients were classified according to their change in OCS use during the trial with the following categories: 90% to 100% decrease, 75% to &lt;90% decrease, 50% to &lt;75% decrease, &gt;0% to &lt;50% decrease, and no improvement (i.e., no change or any increase or lack of asthma control or withdrawal of treatment). Compared with placebo, patients receiving NUCALA 100&nbsp;mg achieved greater reductions in daily maintenance OCS dose, while maintaining asthma control. Sixteen (23%) patients in the group receiving NUCALA 100&nbsp;mg versus 7 (11%) in the placebo group had a 90% to 100% reduction in their OCS dose. Twenty-five (36%) patients in the group receiving NUCALA 100&nbsp;mg versus 37 (56%) in the placebo group were classified as having no improvement for OCS dose. Additionally, 54% of patients receiving NUCALA 100&nbsp;mg achieved at least a 50% reduction in the daily prednisone dose compared with 33% of patients receiving placebo (95% CI for difference: 4%, 37%). An exploratory analysis was also performed on the subgroup of 29 patients in Trial 3 who had an average baseline and screening blood eosinophil count &lt;150&nbsp;cells/mcL. Five (29%) patients in the group receiving NUCALA 100&nbsp;mg versus 0 (0%) in the placebo group had a 90% to 100% reduction in their dose. Four (24%) patients in the group receiving NUCALA 100&nbsp;mg versus 8 (67%) in the placebo group were classified as having no improvement for OCS dose. The ACQ and SGRQ were also assessed in Trial 3 and showed results similar to those in Trial 2.</p><p><u>Lung Function</u></p><p>Change from baseline in mean forced expiratory volume in 1 second (FEV<sub>1</sub>) was measured in all 3 trials and is presented in Table 5. Compared with placebo, NUCALA 100&nbsp;mg did not provide consistent improvements in mean change from baseline in FEV<sub>1</sub>.</p><p><strong>Table 5. Change from Baseline in FEV<sub>1</sub> (mL) in </strong><strong>Severe Asthma Trials</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:620px"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Trial</strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Difference from Placebo in Mean Change from Baseline FEV<sub>1</sub> (mL) (95% CI)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Week 12</strong></p></td><td style="vertical-align:bottom"><p><strong>Week 24</strong></p></td><td style="vertical-align:bottom"><p><strong>Weeks 32/52</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>1<sup>a</sup></p></td><td style="vertical-align:bottom"><p>10 (-87, 108)</p></td><td style="vertical-align:bottom"><p>5 (-98, 108)</p></td><td style="vertical-align:bottom"><p>61 (-39, 161)<sup>b</sup></p></td></tr><tr><td style="vertical-align:bottom"><p>2<sup>c</sup></p></td><td style="vertical-align:bottom"><p>52 (-30, 134)</p></td><td style="vertical-align:bottom"><p>76 (-6, 159)</p></td><td style="vertical-align:bottom"><p>98 (11, 184)<sup>d</sup></p></td></tr><tr><td style="vertical-align:bottom"><p>3<sup>c</sup></p></td><td style="vertical-align:bottom"><p>56 (-91, 203)</p></td><td style="vertical-align:bottom"><p>114 (-42, 271)</p></td><td style="vertical-align:bottom"><p>NA</p></td></tr></tbody></table><p>FEV<sub>1</sub> = Forced Expiratory Volume in 1 Second, CI = Confidence Interval.</p><p><sup>a</sup> Dose = 75 mg intravenous.</p><p><sup>b</sup> Forced expiratory volume in 1 second (FEV<sub>1</sub>) at Week 52.</p><p><sup>c</sup> Dose = 100 mg subcutaneous.</p><p><sup>d</sup> FEV<sub>1</sub> at Week 32.</p><p>The effect of mepolizumab on lung function was also studied in a 12-week placebo-controlled trial enrolling patients with asthma on a moderate dose of ICS with evidence of symptoms and lung function impairment. Enrollment was not dependent on a history of exacerbations or a pre‑specified eosinophil count. Change from baseline in FEV<sub>1</sub> at Week 12 was numerically lower in the mepolizumab treatment groups than the placebo group.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chronic Rhinosinusitis with Nasal Polyps</p><p>A total of 407 adult patients with CRSwNP were evaluated in a randomized, double‑blind, placebo-controlled, multicenter, 52-week trial (NCT03085797). Patients received NUCALA 100&nbsp;mg or placebo administered subcutaneously once every 4 weeks while continuing nasal corticosteroid therapy. Patients must have received background nasal corticosteroid for &ge;8&nbsp;weeks pre‑screening. Patients had recurrent and symptomatic CRSwNP, and had at least 1 surgery for the removal of nasal polyps within the previous 10 years. Patients were required to have nasal obstruction symptoms with a visual analog scale (VAS) score of &gt;5 out of a maximum score of 10. Patients were also required to have an endoscopic bilateral nasal polyp score (NPS) of &sup3;5 out of 8 with NPS &ge;2 in each nasal cavity. Patients reported nasal obstruction VAS scores daily by placing a single mark on a continuous line labeled from 0 (none) to 100 (as bad as you can imagine). The distance along the line was converted to a 0 to 10 point scale for scoring. For NPS, polyps on each side of the nose were graded on a categorical scale (0 = no polyps, 1 = small polyps in the middle meatus not reaching below the inferior border of the middle concha, 2 = polyps reaching below the lower border of the middle turbinate, 3 = large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle concha, 4 = large polyps causing almost complete congestion/obstruction of the inferior meatus) for a total score of 0 to 8. Sinus CT scans were not performed at baseline nor during treatment to evaluate for sinus opacification.</p><p>The co-primary endpoints were change from baseline to Week 52 in total endoscopic NPS (0 to 8 scale) as graded by independent blinded assessors and change from baseline in nasal obstruction VAS score (0 to 10 scale) during Weeks 49 to 52. The key secondary endpoint was the time to first nasal surgery (nasal polypectomy) up to Week 52 in this trial. Other secondary endpoints were change from baseline in loss of smell VAS score during Weeks 49 to 52, and proportion of patients requiring systemic steroids for nasal polyps up to Week 52. All VAS scores were collected daily by the patients and reported on a 0 to 10 scale (0 = none, 10 = as bad as you can imagine).</p><p>The demographics and baseline characteristics of patients in this trial are provided in Table 6.</p><p><strong>Table 6. Demographics and Baseline Characteristics in CRSwNP</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p><strong>N = 407</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean age, years</p></td><td style="vertical-align:top"><p>49</p></td></tr><tr><td style="vertical-align:top"><p>Female, n (%)</p></td><td style="vertical-align:top"><p>143 (35)</p></td></tr><tr><td style="vertical-align:top"><p>White, n (%)</p></td><td style="vertical-align:top"><p>379 (93)</p></td></tr><tr><td style="vertical-align:top"><p>Mean CRSwNP duration in years (SD)</p></td><td style="vertical-align:top"><p>11.4 (8.4)</p></td></tr><tr><td style="vertical-align:top"><p>Patients with &ge;1 surgery in past 10 years (%)</p></td><td style="vertical-align:top"><p>407 (100)</p></td></tr><tr><td style="vertical-align:top"><p>Patients with &ge;3 surgeries in past 10 years (%)</p></td><td style="vertical-align:top"><p>124 (30)</p></td></tr><tr><td style="vertical-align:top"><p>OCS use (&ge;1 course) in past 12 months, n (%)</p></td><td style="vertical-align:top"><p>197 (48)</p></td></tr><tr><td style="vertical-align:top"><p>Mean bilateral endoscopic NPS<sup>a</sup>, (SD), range 0-8</p></td><td style="vertical-align:top"><p>5.5 (1.29)</p></td></tr><tr><td style="vertical-align:top"><p>Mean nasal obstruction VAS score, (SD), range 0-10</p></td><td style="vertical-align:top"><p>9.0 (0.83)</p></td></tr><tr><td style="vertical-align:top"><p>Geometric mean blood eosinophil cells/mcL (95% CI)</p></td><td style="vertical-align:top"><p>390 (360, 420)</p></td></tr><tr><td style="vertical-align:top"><p>Asthma, n (%)</p></td><td style="vertical-align:top"><p>289 (71)</p></td></tr><tr><td style="vertical-align:top"><p>AERD, n (%)</p></td><td style="vertical-align:top"><p>108 (27)</p></td></tr></tbody></table><p>CRSwNP = Chronic Rhinosinusitis with Nasal Polyps, SD = standard deviation, OCS = Oral corticosteroid, NPS = nasal polyp score, VAS = visual analog scale, AERD = Aspirin-exacerbated respiratory disease.</p><p><sup>a</sup>As graded by independent blinded assessors.</p><p><u>Endoscopic Nasal Polyp Score and Nasal Obstruction Visual Analog Scale Scores</u></p><p>Patients who received NUCALA 100 mg had a statistically significant improvement (decrease) in bilateral NPS at Week 52 and nasal obstruction VAS score from Weeks 49 to 52 at the end of the 52 week treatment period (Table 7).</p><p><strong>Table 7. Analyses of Endpoints in CRSwNP</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:654px"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Scores<sup>a</sup></strong></p><p><strong>(range)</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Placebo</strong></p><p><strong>n = 201</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>NUCALA 100 mg</strong></p><p><strong>n = 206</strong></p></td><td rowspan="2" style="vertical-align:bottom"><p><strong>Mean Difference vs. Placebo<br />(95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline Mean</strong></p><p><strong>(SD)</strong></p></td><td style="vertical-align:top"><p><strong>Mean Change<sup>b</sup></strong></p><p><strong>(SE)</strong></p></td><td style="vertical-align:top"><p><strong>Baseline Mean</strong></p><p><strong>(SD)</strong></p></td><td style="vertical-align:top"><p><strong>Mean Change<sup>b</sup></strong></p><p><strong>(SE)</strong></p></td></tr><tr><td style="vertical-align:top"><p>NPS</p><p>(0-8)</p></td><td style="vertical-align:top"><p>5.6</p><p>(1.41)</p></td><td style="vertical-align:top"><p>0.06</p><p>(0.14)</p></td><td style="vertical-align:top"><p>5.4</p><p>(1.17)</p></td><td style="vertical-align:top"><p>-0.87 (0.14)</p></td><td style="vertical-align:top"><p>-0.93</p><p>(-1.31, -0.55)</p></td></tr><tr><td style="vertical-align:top"><p>Nasal obstruction</p><p>(0-10)</p></td><td style="vertical-align:top"><p>9.02</p><p>(0.83)</p></td><td style="vertical-align:top"><p>-2.54</p><p>(0.25)</p></td><td style="vertical-align:top"><p>8.92</p><p>(0.83)</p></td><td style="vertical-align:top"><p>-4.40 (0.25)</p></td><td style="vertical-align:top"><p>-1.86</p><p>(-2.53, -1.19)</p></td></tr></tbody></table><p>CRSwNP = Chronic Rhinosinusitis with Nasal Polyps, SD = standard deviation, SE = standard error, CI = Confidence Interval, NPS = Nasal polyp score at Week 52.</p><p><sup>a</sup>Patients with nasal surgery were assigned worst possible score for the period after nasal surgery. Missing data were imputed based on available off-treatment data across treatment arms. Imputations were made stepwise by visit and conditioned on data from previous visits with the same covariates used in the analysis model.</p><p><sup>b</sup>Least square means from analysis using mixed model repeated measures with covariates of treatment group, geographic region, baseline score, and log(e) baseline blood eosinophil count, visit, interaction terms for visit by baseline and visit by treatment.</p><p><u>Nasal Polypectomy</u></p><p>The key secondary endpoint was the time to first nasal surgery (nasal polypectomy) up to Week 52. The proportion of patients who had surgery was significantly reduced by 57% (hazard ratio: 0.43, 95% CI: 0.25, 0.76) in the group treated with NUCALA 100 mg compared with the placebo group (Figure 2). By Week 52, 18 (9%) patients who received NUCALA 100 mg had surgery compared with 46 (23%) patients in the placebo group.</p><p><strong>Figure 2. Kaplan-Meier Plot of Time to First Nasal Surgery in CRSwNP</strong></p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_18" o:spid="_x0000_i1027" type="#_x0000_t75" style='width:446.25pt;
 height:270pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="595" height="360" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /></p><p>CRSwNP = Chronic Rhinosinusitis with Nasal Polyps, SC = subcutaneous.</p><p><u>Additional CRSwNP Symptoms Scores</u></p><p>For patients who received NUCALA 100 mg, statistically significant improvement was observed in loss of smell compared to placebo and improvements were also observed in the individual VAS symptom scores compared with patients in the placebo group in the 4-weeks prior to the end of the 52-week treatment period (Table 8).&nbsp;</p><p><strong>Table 8: Additional Visual Analog Scale Symptom Scores Assessed at Weeks 49-52</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:640px"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>VAS Scores<sup>a</sup></strong></p><p><strong>(range)</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Placebo</strong></p><p><strong>n = 201</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>NUCALA 100 mg</strong></p><p><strong>n = 206</strong></p></td><td rowspan="2" style="vertical-align:bottom"><p><strong>Mean Difference vs. Placebo</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline Mean</strong></p><p><strong>(SD)</strong></p></td><td style="vertical-align:top"><p><strong>Mean Change<sup>b</sup></strong></p><p><strong>(SE)</strong></p></td><td style="vertical-align:top"><p><strong>Baseline Mean</strong></p><p><strong>(SD)</strong></p></td><td style="vertical-align:top"><p><strong>Mean Change<sup>b</sup></strong></p><p><strong>(SE)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Loss of smell</p><p>(0-10)</p></td><td style="vertical-align:top"><p>9.68 (0.60)</p></td><td style="vertical-align:top"><p>-1.46 (0.24)</p></td><td style="vertical-align:top"><p>9.63 (0.83)</p></td><td style="vertical-align:top"><p>-2.92 (0.24)</p></td><td style="vertical-align:top"><p>-1.46</p><p>(-2.11, -0.81)</p></td></tr><tr><td style="vertical-align:top"><p>Nasal discharge<sup>c</sup></p><p>(0-10)</p></td><td style="vertical-align:top"><p>8.78 (1.25)</p></td><td style="vertical-align:top"><p>-2.49 (0.26)</p></td><td style="vertical-align:top"><p>8.78 (1.07)</p></td><td style="vertical-align:top"><p>-4.38 (0.25)</p></td><td style="vertical-align:top"><p>-1.89</p><p>(-2.58, -1.20)</p></td></tr><tr><td style="vertical-align:top"><p>Mucus in the throat<sup>c</sup></p><p>(0-10)</p></td><td style="vertical-align:top"><p>8.58 (1.63)</p></td><td style="vertical-align:top"><p>-2.37 (0.26)</p></td><td style="vertical-align:top"><p>8.51 (1.61)</p></td><td style="vertical-align:top"><p>-4.07 (0.26)</p></td><td style="vertical-align:top"><p>-1.70</p><p>(-2.41, -0.99)</p></td></tr><tr><td style="vertical-align:top"><p>Facial pain<sup>c</sup></p><p>(0-10)</p></td><td style="vertical-align:top"><p>7.77 (2.72)</p></td><td style="vertical-align:top"><p>-2.04 (0.28)</p></td><td style="vertical-align:top"><p>7.76 (2.51)</p></td><td style="vertical-align:top"><p>-3.73 (0.27)</p></td><td style="vertical-align:top"><p>-1.69</p><p>(-2.43, -0.95)</p></td></tr></tbody></table><p>VAS = Visual Analog Scale; SD = Standard Deviation; SE = Standard Error; CI = Confidence Interval.</p><p><sup>a</sup>Patients with nasal surgery were assigned the worst possible score for the period after nasal surgery. Missing data was imputed based on available off-treatment data across treatment arms. Imputations were made stepwise by visit and conditioned on data from previous visits with the same covariates used in the analysis model.</p><p><sup>b</sup>Least square means from an analysis using mixed model repeated measures with covariates of treatment group, geographic region, baseline score, and log(e) baseline blood eosinophil count visit, interaction terms for visit by baseline and visit by treatment.</p><p><sup>c</sup>This endpoint was not prespecified in the analysis plan to adjust for multiplicity.</p><p><u>Corticosteroid Reduction</u></p><p>Treatment with NUCALA 100 mg significantly reduced the need for systemic steroids for nasal polyps vs. placebo up to Week 52 (odds ratio: 0.58, 95% CI: 0.36, 0.92). In patients who received NUCALA 100 mg, 52 (25%) required &ge;1 course of systemic steroids compared with 74 (37%) in the placebo group throughout the 52-week treatment period.</p><p><u>Results in Patients with Co-morbid Asthma</u></p><p>In 289 (71%) patients with co-morbid asthma, pre-specified analyses showed improvements in the co-primary endpoints consistent with those seen in the overall population in the patients who received NUCALA 100 mg compared with placebo. Additionally, based on a post-hoc analysis in these patients, there was a greater response from baseline at Week 52 in asthma control as measured by the Asthma Control Questionnaire (ACQ‑5) for NUCALA 100 mg compared with placebo (57% of the NUCALA patients met the responder threshold reduction of &ge;0.5, compared to 35% in the placebo group, with an odds ratio of 2.42 (95% CI 1.43, 4.11)).</p><p>&nbsp;</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eosinophilic Granulomatosis with Polyangiitis</p><p>A total of 136 adult patients with EGPA were evaluated in a randomized, placebo-controlled, multicenter, 52-week trial (NCT02020889). Patients received 300 mg of NUCALA or placebo administered subcutaneously once every 4 weeks while continuing their stable OCS therapy. Starting at Week 4, OCS was tapered during the treatment period at the discretion of the investigator. Efficacy was assessed in this trial using co-endpoints of the total accrued duration of remission over the 52‑week treatment period, defined as Birmingham Vasculitis Activity Score (BVAS) = 0 (no active vasculitis) plus prednisolone or prednisone dose less than or equal to 4&nbsp;mg/day, and the proportion of patients in remission at both Week 36 and Week 48 of treatment. The BVAS is a clinician-completed tool to assess clinically active vasculitis that would likely require treatment, after exclusion of other causes.</p><p>The demographics and baseline characteristics of patients in this trial are provided in Table 9.</p><p><strong>Table 9. Demographics and Baseline Characteristics in EGPA</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:bottom"><p><strong>N = 136</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean age, years</p></td><td style="vertical-align:top"><p>48.5</p></td></tr><tr><td style="vertical-align:top"><p>Female, n (%)</p></td><td style="vertical-align:top"><p>80 (59)</p></td></tr><tr><td style="vertical-align:top"><p>White, n (%)</p></td><td style="vertical-align:top"><p>125 (92)</p></td></tr><tr><td style="vertical-align:top"><p>Duration of EGPA, years, mean (SD)</p></td><td style="vertical-align:top"><p>5.5 (4.63)</p></td></tr><tr><td style="vertical-align:top"><p>History of <u>&gt;</u>1 confirmed relapse in past 2 years, n (%)</p></td><td style="vertical-align:top"><p>100 (74)</p></td></tr><tr><td style="vertical-align:top"><p>Refractory disease, n (%)</p></td><td style="vertical-align:top"><p>74 (54)</p></td></tr><tr><td style="vertical-align:top"><p>Recurrence of EGPA symptoms, n (%)</p></td><td style="vertical-align:top"><p>68 (50)</p></td></tr><tr><td style="vertical-align:top"><p>Failed induction treatment, n (%)</p></td><td style="vertical-align:top"><p>6 (4)</p></td></tr><tr><td style="vertical-align:top"><p>Baseline oral corticosteroid<sup>a</sup> daily dose, mg, median (range)</p></td><td style="vertical-align:top"><p>12 (7.5-50)</p></td></tr><tr><td style="vertical-align:top"><p>Receiving immunosuppressive therapy,<sup>b</sup> n (%)</p></td><td style="vertical-align:top"><p>72 (53)</p></td></tr></tbody></table><p>EGPA = Eosinophilic Granulomatosis with Polyangiitis, SD = standard deviation.</p><p><sup>a</sup> Prednisone or prednisolone equivalent.</p><p><sup>b</sup> e.g., Azathioprine, methotrexate, mycophenolic acid.</p><p><u>&nbsp;</u></p><p><u>Remission</u></p><p>Patients receiving 300 mg of NUCALA achieved a significantly greater accrued time in remission compared with placebo. A significantly higher proportion of patients receiving 300&nbsp;mg of NUCALA achieved remission at both Week 36 and Week 48 compared with placebo (Table&nbsp;10). Results of the components of remission are also shown in Table&nbsp;10. In addition, significantly more patients receiving 300&nbsp;mg of NUCALA achieved remission within the first 24&nbsp;weeks and remained in remission for the remainder of the 52-week trial treatment period compared with placebo (19% for 300&nbsp;mg of NUCALA versus 1% for placebo; OR 19.7; 95%&nbsp;CI: 2.3, 167.9).</p><p><strong>Table 10. Remission and Components of Remission in EGPA</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:644px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="6" style="vertical-align:bottom"><p><strong>Remission</strong></p><p><strong>(OCS &le;4 mg/day + BVAS = 0)</strong></p></td><td colspan="6" style="vertical-align:bottom"><p><strong>OCS &le;4 mg/day</strong></p></td><td colspan="6" style="vertical-align:bottom"><p><strong>BVAS = 0</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:bottom"><p><strong>Placebo</strong></p><p><strong>n = 68</strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>NUCALA</strong></p><p><strong>300 mg</strong></p><p><strong>n = 68</strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Placebo</strong></p><p><strong>n = 68</strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>NUCALA</strong></p><p><strong>300 mg</strong></p><p><strong>n = 68</strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Placebo</strong></p><p><strong>n = 68</strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>NUCALA</strong></p><p><strong>300 mg</strong></p><p><strong>n = 68</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="19" style="vertical-align:bottom"><p><strong>Accrued duration over 52 weeks, n (%)</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>0</p></td><td colspan="3"><p>55 (81)</p></td><td colspan="3"><p>32 (47)</p></td><td colspan="3"><p>46 (68)</p></td><td colspan="3"><p>27 (40)</p></td><td colspan="3"><p>6 (9)</p></td><td colspan="2"><p>3 (4)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&gt;0 to &lt;12 weeks</p></td><td colspan="3"><p>8 (12)</p></td><td colspan="3"><p>8 (12)</p></td><td colspan="3"><p>12 (18)</p></td><td colspan="3"><p>5 (7)</p></td><td colspan="3"><p>15 (22)</p></td><td colspan="2"><p>13 (19)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>12 to &lt;24 weeks</p></td><td colspan="3"><p>3 (4)</p></td><td colspan="3"><p>9 (13)</p></td><td colspan="3"><p>6 (9)</p></td><td colspan="3"><p>12 (18)</p></td><td colspan="3"><p>11 (16)</p></td><td colspan="2"><p>5 (7)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>24 to &lt;36 weeks</p></td><td colspan="3"><p>0</p></td><td colspan="3"><p>10 (15)</p></td><td colspan="3"><p>2 (3)</p></td><td colspan="3"><p>10 (15)</p></td><td colspan="3"><p>17 (25)</p></td><td colspan="2"><p>2 (3)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&sup3;36 weeks</p></td><td colspan="3"><p>2 (3)</p></td><td colspan="3"><p>9 (13)</p></td><td colspan="3"><p>2 (3)</p></td><td colspan="3"><p>14 (21)</p></td><td colspan="3"><p>19 (28)</p></td><td colspan="2"><p>45 (66)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Odds ratio (NUCALA/placebo)<sup>a</sup></p><p>(95% CI)</p></td><td colspan="3" style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:bottom"><p>5.9</p><p>(2.7, 13.0)</p></td><td colspan="3" style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:bottom"><p>5.1</p><p>(2.5, 10.4)</p></td><td colspan="3" style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p>3.7</p><p>(1.8, 7.6)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="19" style="vertical-align:bottom"><p><strong>Proportion of patients at both Weeks 36 and 48</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Patients, n (%)</p></td><td colspan="3"><p>2 (3)</p></td><td colspan="3"><p>22 (32)</p></td><td colspan="3"><p>7 (10)</p></td><td colspan="3"><p>28 (41)</p></td><td colspan="3"><p>23 (34)</p></td><td colspan="2"><p>34 (50)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Odds ratio (NUCALA/placebo)<sup>a</sup></p><p>(95% CI)</p></td><td colspan="3" style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:bottom"><p>16.7</p><p>(3.6, 77.6)</p></td><td colspan="3" style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:bottom"><p>6.6</p><p>(2.6, 17.1)</p></td><td colspan="3" style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p>1.9</p><p>(0.9, 4.2)</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>EGPA = Eosinophilic Granulomatosis with Polyangiitis, OCS = Oral Corticosteroid, BVAS = Birmingham Vasculitis Activity Score, CI = confidence interval.</p><p><sup>a</sup>&nbsp; An odds ratio &gt;1 favors NUCALA.</p><p>Additionally, a statistically significant benefit for these endpoints was demonstrated using remission defined as BVAS = 0 plus prednisolone/prednisone &le;7.5&nbsp;mg/day.</p><p><u>Relapse</u></p><p>The time to first relapse (defined as worsening related to vasculitis, asthma, or sino-nasal symptoms requiring an increase in dose of corticosteroids or immunosuppressive therapy or hospitalization) was significantly longer for patients receiving 300 mg of NUCALA compared with placebo with a hazard ratio of 0.32 (95%&nbsp;CI: 0.21, 0.5) (Figure&nbsp;2). Additionally, patients receiving 300 mg of NUCALA had a reduction in rate of relapse compared with patients receiving placebo (rate ratio 0.50; 95%&nbsp;CI: 0.36, 0.70 for 300&nbsp;mg of NUCALA compared with placebo). The incidence and number of relapse types (vasculitis, asthma, sino-nasal) were numerically lower with NUCALA compared with placebo.</p><p><strong>Figure 3. Kaplan-Meier Plot of Time to First Relapse in EGPA</strong></p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_14" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:429pt;
 height:214.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image005.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="572" height="286" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image006.jpg" /></p><p>EGPA = Eosinophilic Granulomatosis with Polyangiitis, SC = subcutaneous.</p><p><u>Corticosteroid Reduction</u></p><p>Patients receiving 300&nbsp;mg of NUCALA had a significantly greater reduction in average daily OCS dose compared with patients receiving placebo during Weeks 48 to 52 (Table&nbsp;11).</p><p><strong>Table&nbsp;11. Average Daily Oral Corticosteroid Dose during Weeks 48 to 52 in EGPA</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:639px"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Number (%) of Patients</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Placebo</strong></p><p><strong>n = 68</strong></p></td><td style="vertical-align:top"><p><strong>NUCALA</strong></p><p><strong>300 mg</strong></p><p><strong>n = 68</strong></p></td></tr><tr><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2 (3)</p></td><td style="vertical-align:top"><p>12 (18)</p></td></tr><tr><td style="vertical-align:top"><p>&gt;0 to &le;4.0 mg</p></td><td style="vertical-align:top"><p>3 (4)</p></td><td style="vertical-align:top"><p>18 (26)</p></td></tr><tr><td style="vertical-align:top"><p>&gt;4.0 to &le;7.5 mg</p></td><td style="vertical-align:top"><p>18 (26)</p></td><td style="vertical-align:top"><p>10 (15)</p></td></tr><tr><td style="vertical-align:top"><p>&gt;7.5 mg</p></td><td style="vertical-align:top"><p>45 (66)</p></td><td style="vertical-align:top"><p>28 (41)</p></td></tr><tr><td style="vertical-align:top"><p>Comparison: NUCALA/placebo<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Odds ratio<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.20</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.09, 0.41</p></td></tr></tbody></table><p>EGPA = Eosinophilic Granulomatosis with Polyangiitis, CI = confidence interval.</p><p><sup>a</sup> Analyzed using a proportional odds model with covariates of treatment group, baseline oral corticosteroid daily dose, baseline Birmingham Vasculitis Activity Score, and region.</p><p><sup>b</sup> An odds ratio &lt;1 favors NUCALA.</p><p><u>Asthma Control Questionnaire-6 (ACQ-6)</u></p><p>The ACQ-6, a 6-item questionnaire completed by the patient, was developed to measure the adequacy of asthma control and change in asthma control. The on-treatment ACQ-6 responder rate during Weeks 48 to 52 (defined as a decrease in score of 0.5 or more compared with baseline) was 22% for 300&nbsp;mg of NUCALA and 16% for placebo (OR 1.56; 95%&nbsp;CI: 0.63, 3.88 for 300&nbsp;mg of NUCALA compared with placebo).</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypereosinophilic Syndrome</p><p>A total of 108 adult and adolescent patients aged 12 years and older with HES for at least 6 months were evaluated in a randomized, double-blind, placebo-controlled, multicenter, 32-week trial (NCT02836496). Patients with non-hematologic secondary HES (e.g., drug hypersensitivity, parasitic helminth infection, HIV infection, non-hematologic malignancy) or FIP1L1-PDGFR&alpha; kinase-positive HES were excluded from the trial. Patients received 300&nbsp;mg of NUCALA or placebo subcutaneously once every 4 weeks while continuing their stable HES therapy. Patients entering the trial had experienced at least 2 HES flares within the past 12 months and a blood eosinophil count of 1,000 cells/mcL or higher during screening. Historical HES flares for the trial entry criteria were defined as HES‑related worsening of clinical symptoms or blood eosinophil counts requiring an escalation in therapy. Patients must have been on stable HES therapy for the 4&nbsp;weeks prior to randomization. HES therapy could include chronic or episodic oral corticosteroids (OCS), immunosuppressive, or cytotoxic therapy.</p><p>The efficacy of NUCALA in HES was established based upon the proportion of patients who experienced a HES flare during the 32-week treatment period. A HES flare was defined as worsening of clinical signs and symptoms of HES or increasing eosinophils (on at least 2 occasions), resulting in the need to increase OCS or increase/add cytotoxic or immunosuppressive HES therapy.</p><p>The demographics and baseline characteristics of patients in this trial are provided in Table 12.</p><p><strong>Table 12. Demographics and Baseline Characteristics in HES</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p><strong>N = 108</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean age, years (SD)</p></td><td style="vertical-align:top"><p>46.0 (15.78)</p></td></tr><tr><td style="vertical-align:top"><p>Female, n (%)</p></td><td style="vertical-align:top"><p>57 (53)</p></td></tr><tr><td style="vertical-align:top"><p>White, n (%)</p></td><td style="vertical-align:top"><p>100 (93)</p></td></tr><tr><td style="vertical-align:top"><p>Mean duration of HES, years</p></td><td style="vertical-align:top"><p>5.55</p></td></tr></tbody></table><p>HES = Hypereosinophilic Syndrome, SD = standard deviation.</p><p><u>Flares</u></p><p>The trial compared the proportion of patients who experienced a HES flare or withdrew from the trial in the NUCALA and placebo treatment groups (Table&nbsp;13). Over the 32-week treatment period, the incidence of HES flare over the treatment period was 56% for the placebo group and 28% for the group treated with NUCALA (50% reduction).</p><p><strong>Table 13. Overview of HES Flares</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Number (%) of Patients</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Placebo</strong></p><p><strong>n = 54</strong></p></td><td style="vertical-align:top"><p><strong>NUCALA</strong></p><p><strong>300 mg</strong></p><p><strong>n = 54</strong></p></td></tr><tr><td style="vertical-align:top"><p>Patients with &ge;1 HES flare or who withdrew from trial</p></td><td style="vertical-align:top"><p>30 (56)</p></td><td style="vertical-align:top"><p>15 (28)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Patients with &ge;1 HES flare</p></td><td style="vertical-align:top"><p>28 (52)</p></td><td style="vertical-align:top"><p>14 (26)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Patients with no HES flare who withdrew from trial</p></td><td style="vertical-align:top"><p>2 (4)</p></td><td style="vertical-align:top"><p>1 (2)</p></td></tr><tr><td style="vertical-align:top"><p>Comparison: NUCALA/placebo<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>CMH <em>P </em>value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.002</p></td></tr><tr><td style="vertical-align:top"><p>Odds ratio<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.28</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.12, 0.64)</p></td></tr></tbody></table><p>HES = Hypereosinophilic Syndrome, CMH = Cochran-Mantel-Haenszel, CI = confidence interval.</p><p><sup>a</sup> Analysis compared the number of patients who experienced &ge;1 HES flare and/or withdrew from the trial prematurely.</p><p><sup>b</sup> An odds ratio &lt;1 favors NUCALA.</p><p><u>Time to First Flare</u></p><p>Difference was observed between NUCALA and placebo arms in the time to first HES flare (Figure 4). The risk of first HES flare over the treatment period was 66&nbsp;% lower for patients treated with NUCALA compared with placebo (Hazard Ratio: 0.34; 95&nbsp;% CI 0.18, 0.67, <em>P</em>&nbsp;=&nbsp;0.002).</p><p><strong>Figure 4. Kaplan-Meier Curve for Time to First HES</strong><strong> Flare</strong></p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_3" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:406.5pt;
 height:233.25pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image007.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="542" height="311" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image008.jpg" /></p><p>HES = Hypereosinophilic Syndrome, SC = subcutaneous.</p><p><u>Proportion of Patients Who Experienced Flares during Week 20 through Week 32</u></p><p>From Week 20 through Week 32, significantly fewer patients experienced a HES flare or withdrew from the trial when treated with 300 mg of NUCALA compared with placebo (17% vs. 35%, respectively, <em>P</em> = 0.020; OR: 0.33; 95&nbsp;% CI: 0.13, 0.85).</p><p><u>Rate of Flares</u></p><p>Patients who received NUCALA experienced significantly fewer HES flares during the 32-week treatment period compared with the placebo group (Table 14). Treatment with NUCALA resulted in a statistically significant 66% reduction in the annualized rate of HES flares compared with placebo.</p><p><strong>Table&nbsp;14. Frequency of</strong><strong> Flares</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Number (%) of Patients</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Placebo</strong></p><p><strong>n = 54</strong></p></td><td style="vertical-align:top"><p><strong>NUCALA</strong></p><p><strong>300 mg</strong></p><p><strong>n = 54</strong></p></td></tr><tr><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>26 (48)</p></td><td style="vertical-align:top"><p>40 (74)</p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>15 (28)</p></td><td style="vertical-align:top"><p>11 (20)</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>7 (13)</p></td><td style="vertical-align:top"><p>3 (6)</p></td></tr><tr><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>5 (9)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>1 (2)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&ge;5</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Comparison: NUCALA/placebo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Wilcoxon <em>P</em> value (unadjusted/adjusted)<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.002/0.02</p></td></tr><tr><td style="vertical-align:top"><p>Rate/year</p></td><td style="vertical-align:top"><p>1.46</p></td><td style="vertical-align:top"><p>0.50</p></td></tr><tr><td style="vertical-align:top"><p>Rate ratio<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.34</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.19, 0.63)</p></td></tr></tbody></table><p>CI = confidence interval.</p><p><sup>a</sup> Adjusted <em>P</em> values based on pre-specified hierarchy of endpoints.</p><p><sup>b</sup> A rate ratio &lt;1 favors NUCALA.</p><p><u>Brief Fatigue Inventory</u></p><p>Brief Fatigue Inventory (BFI) Item&nbsp;3 asks patients to record their worst level of weariness/tiredness severity during the past 24 hours (scale: 0 = no fatigue to 10 = as bad as you can imagine). At baseline, median BFI Item&nbsp;3 scores were similar between treatment groups (4.46 for NUCALA 300 mg and 4.69 for placebo). At Week 32, BFI Item 3 scores improved with NUCALA compared with placebo (<em>P </em>= 0.036). The median change from baseline score for BFI Item 3 at Week 32 was -0.66 in the group treated with NUCALA and 0.32 in the placebo group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carcinogenesis, Mutagenesis, Impairment of Fertility</p><p>Long-term animal studies have not been performed to evaluate the carcinogenic potential of mepolizumab. Published literature using animal models suggests that IL-5 and eosinophils are part of an early inflammatory reaction at the site of tumorigenesis and can promote tumor rejection. However, other reports indicate that eosinophil infiltration into tumors can promote tumor growth. Therefore, the malignancy risk in humans from an antibody to IL-5 such as mepolizumab is unknown.</p><p>Male and female fertility were unaffected based upon no adverse histopathological findings in the reproductive organs from cynomolgus monkeys receiving mepolizumab for 6&nbsp;months at IV dosages up to 100 mg/kg once every 4 weeks (approximately 20 times the MRHD of 300 mg on an AUC basis). Mating and reproductive performance were unaffected in male and female CD-1 mice receiving an analogous antibody, which inhibits the activity of murine IL-5, at an IV dosage of 50&nbsp;mg/kg once per week.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Excipient Name</strong></p></td><td style="vertical-align:top"><p><strong>Quantity&nbsp; </strong></p></td><td style="vertical-align:top"><p><strong>Unit</strong></p></td></tr><tr><td style="vertical-align:top"><p>Sucrose</p></td><td style="vertical-align:top"><p>120</p></td><td style="vertical-align:top"><p>mg</p></td></tr><tr><td style="vertical-align:top"><p>Sodium phosphate dibasic heptahydrate</p></td><td style="vertical-align:top"><p>4.16</p></td><td style="vertical-align:top"><p>mg</p></td></tr><tr><td style="vertical-align:top"><p>Citric acid monohydrate</p></td><td style="vertical-align:top"><p>0.95</p></td><td style="vertical-align:top"><p>mg</p></td></tr><tr><td style="vertical-align:top"><p>Polysorbate 80</p></td><td style="vertical-align:top"><p>0.20</p></td><td style="vertical-align:top"><p>mg</p></td></tr><tr><td style="vertical-align:top"><p>EDTA disodium dehydrate</p></td><td style="vertical-align:top"><p>0.019</p></td><td style="vertical-align:top"><p>mg</p></td></tr><tr><td style="vertical-align:top"><p>Water for injection</p></td><td style="vertical-align:top"><p>QS 1</p></td><td style="vertical-align:top"><p>mL</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No incompatibilities have been identified.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in refrigerator (2-8&ordm;C).</p><p>Do not freeze.</p><p>Protect from light. Store in the original carton until use.</p><p>The pre-filled pen and pre-filled syringe can be removed from the refrigerator and kept in the unopened carton for up to 7 days at room temperature (up to 30&deg;C), when protected from light. Discard if left out of the refrigerator for more than 7 days.</p><p>The pre-filled pen or pre-filled syringe must be administered within 8 hours once the pack is opened. Discard if not administered within 8 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Solution for injection in pre-filled pen (auto-injector) </u></p><p>1&nbsp;mL siliconised, Type I glass syringe with 0.5 inch (12.7 mm), 29&nbsp;gauge, stainless steel needle assembled as an auto-injector.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>See the Instructions for Use in the leaflet for complete administration instructions with illustrations.</p><p>Not all presentations are available in every country.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                7.	MARKETING AUTHORISATION HOLDER:
Glaxo Saudi Arabia Ltd.*, Jeddah, Kingdom of Saudi Arabia. 

8.	MANUFACTURED BY:
Glaxo Operations UK Ltd*, Barnard Castle, UK
*member of the GSK group of companies

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                US CPI Version_29 July 2021
NUCALA is a trademark owned by or licensed to the GSK group of companies.

©2021 GSK group of companies. All rights reserved.

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>